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Resumo 
O desenvolvimento de novas terapias, de vacinas e a aplicação dos 
vírus no tratamento do cancro será melhor sucedido quanto mais 
abrangente e aprofundado for o conhecimento da interacção entre o vírus 
e o hospedeiro. 
Esta tese tem como objectivo global compreender a interacção 
entre o vírus do sarampo e o hospedeiro e as consequências dessa 
interacção no tropismo e patogénese viral. Em particular, pretende-se 
identificar as células alvo iniciais do vírus bem como as células responsáveis 
pela disseminação do vírus no hospedeiro. Pretende-se ainda compreender 
os mecanismos de atenuação do vírus atenuado do sarampo.  
O vírus do sarampo é transmitido através de aerossóis e, apesar da 
infecção ter início no aparelho respiratório, as células alvo iniciais do vírus 
não são conhecidas. A partir do aparelho respiratório o vírus alcança os 
orgãos linfáticos e inicia a replicação nos nódulos linfaticos que drenam o 
aparelho respiratório.  
Apesar de vários estudos terem sido desenvolvidos, a contribuição 
da interacção entre os receptores e o vírus no tropismo viral e progressão 
da infecção têm sido restringidos pela falta de um modelo animal 
adequado. Os macacos são os únicos primatas não humanos que mostram 
susceptibilidade ao vírus do sarampo. No entanto, o seu uso fica muito 
limitado devido a questoes éticas e monetárias. O vírus wild type do 
sarampo utiliza como receptor celular uma proteína expressa em células 
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activadas do sistema imune denominada de molécula de sinalização de 
activação linfocitária (SLAM, CD150). Com o objectivo de desenvolver um 
modelo animal para o estudo da infecção pelo vírus do sarampo, ratinhos 
transgénicos SLAMGe, ratinhos que expressam o SLAM humano (hSLAM), 
foram cruzados com ratinhos que apresentam inactivação do gene que 
codifica para o receptor do interferão tipo I, ratinhos Ifnar
ko
,
 
de forma a 
permitir uma replicação do vírus mais eficiente. Os ratinhos resultantes do 
cruzamento foram denominados ratinhos Ifnar
ko
-SLAMGe. São deficientes 
na produção de interferão tipo I e expressam hSLAM com um perfil de 
expressão idêntico ao dos humanos. Estes ratinhos foram utilizados neste 
estudo para caracterizar as células infectadas pelo vírus do sarampo 
imediatamente após infecção respiratória bem como as células 
responsáveis pela progressão e disseminação do vírus no hospedeiro.  
Em primeiro lugar caracterizamos a expressão do hSLAM nos 
ratinhos Ifnar
ko
-SLAMGe. A expressão de hSLAM foi detectada em linfócitos 
B e T extraídos do baço e em macrófagos produzidos a partir da medula 
óssea, através de citometria de fluxo, após activação destas células ex vivo. 
Uma vez que o linfonodo mediastinal foi previamente demonstrado ser 
relevante na infecção pelo vírus do sarampo em ratinhos SLAM, estudamos 
a expressão de hSLAM em células imunes provenientes do linfonodo 
mediastinal de ratinhos Ifnar
ko
-SLAMGe. Através de citometria de fluxo 
demonstramos que os linfócitos B e T não activados provenientes do 
linfonodo mediastinal expressavam baixos níveis de hSLAM. 
Documentamos ainda que, mais células B do que células T expressavam 
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hSLAM, como previamente demonstrado em tecidos linfáticos humanos. 
Uma vez que SLAM é expresso em células imunes e não em células 
epiteliais, as células imunes presentes nas vias respiratórias são candidatas 
a células alvo para a replicação do vírus. Desta forma, analizamos a 
expressão de hSLAM em células imunes provenientes dos pulmões do 
ratinho Ifnar
ko
-SLAMGe. Cerca de 9% de células B e 3% de células T 
expressavam hSLAM nos pulmões do ratinho Ifnar
ko
-SLAMGe e baixa 
percentagem de macrófagos alveolares expressavam hSLAM. 
De seguida, estes ratinhos foram inoculados via intranasal (IN) com 
o vírus do sarampo wild type. Um vírus derivado da estírpe Ichinoise B e ao 
qual foi adicionado o gene que codifica para a expressão da proteína verde 
fluorescente, wtMVgreen. Vários orgãos foram recolhidos um, dois e três 
dias após a inoculação e analizados para a expressão de proteína 
fluorescente. Um dia após inoculação a replicação viral foi detectada nos 
pulmões, e, de seguida, em vários orgãos do sistema linfático; inicialmente 
no linfonodo que drena o aparelho respiratório, o linfonodo mediatinal, e 
mais tarde em outros orgãos linfáticos, nomeadamente nos linfonodos 
mandibular, inguinal e mesentérico, no baço e em células mononucleares 
do sangue periférico.  
Para responder à questão quais as células que sustentam a 
replicação do vírus imediatamente após inoculação, os ratinhos foram 
inoculados via IN com wtMVgreen; os pulmões e vários orgãos linfáticos 
foram recolhidos e as células infectadas foram identificadas pela expressão 
de proteína verde fluorescente através de citometria de fluxo.  
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Os macrófagos alveolares foram identificados como as principais 
células que sustêm a replicação do vírus do sarampo imediatamente após 
inoculação respiratória. As células dendríticas foram 5 vezes menos 
infectadas. Outras populações de células imunes foram infectadas em 
menor extensão.  
Apesar da expressão de SLAM pelos macrófagos alveolares ser 
muito reduzida, 24 horas apos a infecção a expressão de SLAM aumentou 
drasticamente; 0.86% de macrófagos alveolares expressava SLAM antes da 
infecção, passando 16% a expressarem SLAM após a infecção. Este 
resultado sugere que o vírus do sarampo utiliza um receptor celular que é 
facilmente induzido nas células alvo, contribuindo assim para uma rápida e 
eficiente disseminação no hospedeiro. 
Dois dias após a inoculação IN o vírus propagou-se ao sistema 
linfático sendo o linfonodo mediastinal o primeiro orgão linfático a ser 
infectado e o que suportou título viral mais elevado. Através de citometria 
de fluxo identificaram-se os linfócitos B e T como as principais células 
infectadas bem como células dendríticas, pese embora em menor grau. 
Por último, com o objectivo de compreender os mecanismos de 
atenuação da estírpe do vírus usada como vacina do sarampo, foi 
caracterizada a infecção e disseminação do vírus do sarampo atenuado, 
denominado aqui de MVvac. Ratinhos Ifnar
ko
-SLAMGe foram inoculados 
com MVvac pela via de infecção intraperitoneal (IP) e o título viral foi 
determinado em vários orgãos linfáticos (nomeadamente nos linfonodos 
mandibular, mediastinal, mesentérico e inguinal e no baço). A replicação 
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do vírus atenuado nos orgãos do ratinho foi muito baixa comparada com a 
replicação do wild type. Três dias após inoculação, o orgão que apresentou 
um título viral mais elevado foi o linfonodo mediastinal seguido do 
linfonodo mesentérico e do baço. A replicação nos linfonodos mandibular e 
inguinal ficou aquém do limite de detecção. Apesar de o linfonodo 
mediastinal ser o orgão linfático onde o vírus mais eficientemente se 
replicou a replicação neste linfonodo pelo MVvac foi cerca de 100 vezes 
inferior à replicação pelo vírus wild type. De seguida, as células que 
sustentam a replicação deste vírus bem como do wild type foram 
identificadas. Um e três dias após a infecção, o linfonodo mediastinal e o 
baço foram recolhidos e secções destes orgãos foram analisadas através de 
microscopia confocal. Um dia após inoculação, ambos os vírus infectaram 
uma população de macrófagos presente na região subcapsular dos 
linfonodo e na zona marginal do baço, denominados macrófagos do seio 
subcapsular (macrófagos SSC). Após uma primeira interacção com os 
macrófagos, foi observada uma disseminação generalizada do vírus do wild 
type nos folículos do linfonodo bem como na polpa branca do baço. Em 
contraste, quando os ratinhos foram inoculados com um vírus do sarampo 
atenuado, apesar de o vírus ser encontrado na região subcaspular do 
linfonodo e zona marginal do baço no primeiro dia após infecção, 
colocalizando com os macrófagos SSC, esta infecção inicial não foi seguida 
de infecção massiva das células linfáticas nestes orgãos. O vírus foi 
eliminado, observando-se apenas alguma replicação no linfonodo 
mediastinal e baço mas inferior à replicação pelo wild type.  
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Ainda com o objectivo de esclarecer o mecanismo de atenuação do 
vírus do sarampo atenuado caracterizamos a replicação de um virus wild 
type com uma substitução de um aminoácido na proteína hemaglutinina. 
Esta mutação, asparagina por tirosina, no aminoácido 481 na proteína 
hemaglutinina (N481Y), está presente em todas as estirpes atenuadas do 
vírus do sarampo mas não no vírus wild type. Esta substituição introduzida 
no genoma do vírus wild type permite ao vírus, que apenas usa o SLAM 
como receptor celular, passar também a utilizar o receptor CD46. O 
receptor CD46 ou cofactor proteico membranar (MCP) é expresso em 
todas as células nucleadas do corpo humano. Todas estirpes atenuadas do 
vírus do sarampo para além de SLAM utilizam o CD46 como receptor 
celular. Para aceitar ou revogar a hipótese de que esta mutação presente 
no vírus atenuado pode afectar o fitness do vírus, introduzimos esta 
mutação num vírus wild type, denominado aqui wtMVN481Y e 
comparamos a replicação in vivo deste vírus com um vírus wild type 
original, wtMV. Para tal, ratinhos Ifnar
ko
-SLAMGe forma inoculados via IP 
com wtMVN481Y ou wtMV. Três dias após inoculação, o título do vírus foi 
determinado em vários linfonodos e no baço. Demonstramos que esta 
mutação não afecta a replicação nem o tropismo do vírus uma vez que não 
se verificaram diferenças relevantes na replicação dos vírus nos diferentes 
orgãos. De seguida, para compreender se a interacção com o receptor 
CD46 para além do SLAM afecta a replicação e disseminação do vírus, 
obtivemos ratinhos transgénicos que expressam o CD46 humano (hCD46) 
para além do hSLAM, aqui denominados de ratinhos Ifnar
ko
-CD46Ge-
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SLAMGe. Inoculamos ratinhos Ifnar
ko
-CD46Ge-SLAMGe e ratinhos Ifnar
ko
-
SLAMGe com o vírus wtMVN481Y e comparamos a replicação e 
disseminação deste vírus em vários orgãos linfáticos destes ratinhos. Não 
foram encontradas diferenças significativas na replicação e tropismo deste 
vírus o que sugere que o uso do receptor CD46 é pouco relevante na 
atenuação do vírus do sarampo. 
Este estudo demonstra que os macrófagos e as células dendríticas 
são as células alvo iniciais do vírus do sarampo e que podem estar 
envolvidas na rápida disseminação do vírus para outras células imunes no 
organismo. Demonstra-se ainda que, os macrófagos como células alvo 
iniciais, aliado à baixa replicação do vírus do sarampo atenuado parecem 
desempenhar um papel importante na atenuação deste vírus. O uso do 
receptor CD46 parece ser pouco relevante no mecanismo de atenuação do 
vírus. Para além disso, a linha de ratinhos transgénicos que expressam o 
receptor hSLAM são uma peça chave no estudo das fases iniciais de 
infecção do vírus do sarampo. 
 
Palavras Chave: macrófagos alveolares, células dendríticas, vírus do 
sarampo, SLAM, CD46, tropismo. 
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Abstract 
 Measles virus (MV) is one of the most infectious viruses but several 
aspects of MV biology and pathogenesis remain poorly understood. The 
virus is transmitted by aerosol droplets and initial infection is believed to 
occur in the upper airways but the cells that support early infection and 
viral spread throughout the body are not well defined. As wild type MV 
(wtMV) enters cells through SLAM but not CD46 receptor, we generated a 
transgenic mice expressing human SLAM (hSLAM) and used these mice to 
identify the cells supporting primary MV infection. We first characterized 
hSLAM expression in immune cells of these mice by flow cytometry. We 
documented hSLAM expression in resting B and T cells in the mediastinal 
lymph node (LN) and in B and T cells and in a small fraction of alveolar 
macrophages (AM) collected from the lungs. Next, we inoculated these 
animals intranasally and assessed viral infection in the nasal associated 
lymphoid tissue, lungs, several LN, spleen and thymus. One day post 
inoculation (p.i.), viral replication was documented in the lungs; the AM 
and dendritic cells (DC) were the main infected cells. It was observed that 
MV infection temporarily enhanced hSLAM expression in AM. From the 
lungs, infection spread to all lymphatic organs and in particular to the 
mediastinal LN. This LN supported high levels of infection upon IN and 
intraperitoneal inoculation. Finally, to understand the mechanisms of MV 
vaccine attenuation, we compared the spread of wtMV with that of a 
vaccine strain (MVvac) in Ifnar
ko
-SLAM mice. One day p.i. MV was detected 
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in the subcapsular macrophages in the mediastinal LN. Three days later, 
the wtMV spread to hSLAM expressing leukocytes whereas the MVvac was 
cleared. As the wtMV does not enter cells through CD46 receptor but the 
attenuated strain does, we compared the replication of a wtMV carrying a 
mutation in the hemagglutinin protein allowing CD46 usage. CD46 usage 
seems to have no relevant effect on MV attenuation. Thus, SLAM 
expressing mice allowed characterization of the early steps of MV 
infection. The alveolar macrophages and dendritic cells are the key players 
in MV infection and propagation. 
 
Keywords: alveolar macrophages, dendritic cells, measles virus, SLAM, 
CD46, tropism. 
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aa amino acid  
APC antigen presenting cell 
APC-Cy7 allophycocyanin-Cy7 
B95a marmoset B-cell line 
BM bone marrow 
CAT chloramphenicol acetyltransferase 
CCPs complement control protein repeats 
CD46 membrane cofactor protein 
cDNA complementary DNA 
CDV canine distemper virus 
Cyt cytoplasmic 
DAPI 4',6-diamidino-2-phenylindole 
DC dendritic cells 
DMEM dulbeco’s modified eagle medium 
DNA deoxyribonucleic acid 
EDTA ethylenediaminetetraacetic acid 
ER endoplasmic reticulum 
F fusion 
FACS flow activated cell sorter 
FBS fetal bovine serum 
FITC fluorescein isothiocyanate 
G guanosine 
GFP green fluorescent protein 
GM-CSF granulocyte-macrophage colony-stimulating factor 
H hemagglutinin 
hCD46 human CD46 
hSLAM human SLAM 
HδR hepatitis delta virus ribozyme 
i.e. id est 
IC-B ichinoise-B 
IFN interferon 
IFNAR interferon type I receptor  
Ifnar
ko
 interferon type I receptor knock out 
Abbreviations 
 
 
xxii 
 
Ig immunoglobulin 
IL interleukin 
IN intranasal 
IP intraperitoneal 
IRF IFN regulatory factor 
ISGF3 IFN-stimulated gene factor 3 
ISRE IFN-stimulated response element 
Kb kilobase 
kDa kilo Dalton 
KO knock out 
L large 
LcK lymphocyte protein tyrosine kinase    
LN lymph node 
LPS lipopolysaccharide 
M matrix 
M.O.I. multiplicity of Infection 
MCP membrane cofactor protein 
MDA-5 melanoma differentiation-associated gene 5 
mL milliliter 
Mm millimeter 
mM millimolar 
mRNA messenger RNA 
MHC major histocompatibility complex 
MS marginal sinus 
MV measles virus 
MW molecular weight 
N nucleocapsid 
NALT nasal associated lymphoid tissue 
Nm nanometer 
ºC degree celsius 
ORF overlapping reading frame 
P phosphoprotein 
p.i. post infection 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
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PCT C-terminal domain 
PE phycoerythrin 
PerCP peridin chorophyll protein 
PNT N-terminal domain 
PRRs pattern-recognition receptors 
RdRp RNA dependent RNA polymerase 
RIG-I retinoic acid-inducible gene I 
RLRs retinoic acid-inducible gene I (RIG-I)-like receptors 
RNA ribonucleic acid 
RNP ribonucleocapsid 
Rpm revolutions per minute 
RPMI Roswell Park Memorial Institute 
RT room temperature 
SAP SLAM-associated protein 
SCR short consensus repeats 
SCS subcapsular Sinus 
SDS-PAGE sodium dedecyl sulfate-polyacrylamide gel electrophoresis 
SLAM signaling lymphocytic activation molecule 
SSPE subacute sclerosing panencephalitis 
STAT signal transducers and activators of transcription 
STP serine-threonine-proline 
TBS tris-buffered saline 
TCID50 tissue culture infectious dose 50% 
Th2 T helper 2 
TLC thin layer chromatography 
TLRs toll-like receptors 
TNF-α tumor necrosis factor alpha 
Tyr110 tyrosine 110 
UV ultra violet 
VSV vesicular stomatitis virus 
WT wild type 
μg microgram 
μl microlitre 
μm micrometer 
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1.1. Taxonomy 
Measles virus (MV) is a member of the family Paramyxoviridae, genus 
Morbillivirus within the Mononegavirales order. The Paramyxoviridae are 
enveloped viruses with a single-stranded nonsegmented RNA genome of 
negative polarity. This family includes some of the most relevant pathogens 
of humans and animals (Table 1). 
 
Family 
 
Subfamily Genus Species 
Paramyxoviridae Paramyxovirinae Respirovirus Bovine parainfluenza virus 
3 
   Human parainfluenza virus 
1 and 3 
   Sendai virus 
    
  Rubulavirus Human parainfluenza virus 
2, 4a and 4b 
   Parainfluenza virus 5  
   Mumps virus 
    
  Morbillivirus Canine distemper virus 
   Dolphin morbillivirus 
   Cetacean morbillivirus 
   Measles virus  
   Peste-des-petits-ruminants 
virus 
   Phocine distemper virus 
   Rinderpest virus 
    
  Avulavirus Newcastle disease virus 
    
General Introduction 
 
4 
 
 
Family 
 
Subfamily Genus Species 
Paramyxoviridae 
 
Pneumovirinae Pneumovirus Bovine respiratory syncytial 
virus 
   Human respiratory 
syncytial virus 
   Ovine respiratory syncytial 
virus 
   Pneumonia virus of mice 
    
  Henipaviruses Hendra virus 
   Nipah virus 
    
    
Table 1. Examples of members of the family Paramyxoviridae. (Adapted 
from Lamb, R.A. and Parks, G.D., Fields Virology, 2007). 
 
 
1.2. History of measles 
Measles is postulated to have emerged in the early civilization centers 
in the Middle East around 3000 B.C.. Abu Becr is known as the first to 
distinguishing measles from smallpox in the 9
th
 century. Many of the 
epidemiological aspects of measles were elucidated by a young Danish 
physician during a measles epidemic in 1846 in the Faroe Islands. He 
postulated the respiratory route of transmission, the highly contagious 
nature of the disease, a 14 days incubation period and the lifelong 
immunity present in the older population (135). In 1790, an English 
surgeon described measles complications, namely a case of post-measles 
encephalomyelitis in a young woman who developed paresis as the rash 
started to fade (103). Nineteenth century text books associated measles 
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infection with reactivation of latent tuberculosis and immunosuppression 
caused by MV is connoted to von Pirquet, who observed, in 1908, 
suppression of the tuberculin test response during measles (197).   
 
1.3. Clinical features of measles 
Measles is transmitted by aerosol droplets, and initial infection is 
believed to be established in the respiratory tract although primary target 
cells are not well defined. From the respiratory tract the virus spreads to 
the regional lymph nodes where viral amplification occurs resulting in 
viremia. The disease is characterized by an incubation period of 10-14 days, 
followed by a 2 to 4 days of prodrome of fever, anorexia, cough and 
conjunctivitis (59). During this phase, small white spots, Koplik’s spots, may 
become visible in the buccal mucosa and are pathognomonic of measles 
(90). The appearance of a maculopapular rash marks the end of the 
prodrome and lasts 3 to 4 days. Recovery begins soon after onset of the 
rash (59) with the appearance of a marked cellular and humoral immune 
response conferring lifelong protective immunity (135). Concomitantly with 
activation of the immune system a transient but profound 
immunosuppression occurs. This immunosuppression continues for weeks 
after apparent recovery and increases the host’s susceptibility to 
opportunistic infections which accounts for measles associated deaths. 
Several complications are associated with measles, including pneumonia, 
encephalitis, otitis media, blindness, and secondary infections by bacteria 
and viruses. Interstitial pneumonia caused by MV replication and 
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inflammation in the lower respiratory tract can occur in healthy patients 
(58, 68) whereas giant cell pneumonia is seen mostly in 
immunocompromised individuals (131). Diarrhea is a common 
gastrointestinal complication of measles and frequently is associated with 
bacterial infections.  
A rare complication of measles is subacute sclerosing 
panencephalitis (SSPE). SSPE is caused by a progressive dissemination of 
defective virus replication in the central nervous system and occurs in 
young individuals several years after infection (91, 122). In about 1 in 1000 
cases measles is complicated by a post-infectious encephalitis that usually 
occurs within 14 days after the onset of rash and mostly in individuals 
under the age of 2 years (83). In contrast to SSPE, little evidence of viral 
invasion of the central nervous system is observed and pathological studies 
suggest an autoimmune etiology (51). Another measles-induced 
neurological complication is measles inclusion body encephalitis or 
progressive infectious encephalitis. It occurs 3 to 6 months after the 
regular disease and is seen in immunocompromised individuals (115).  
 
1.4. Basic biology 
1.4.1. Virion structure and genome 
Measles viral particles are pleomorphic or spherical with diameters 
ranging from 120 to 300-1000 nm and therefore have variable cargo 
volume and tolerate well foreign gene insertion (59, 148). The envelope, 
composed of a lipid bilayer derived from the plasma membrane of the host 
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cell, surrounds the virions and contains surface projections composed by 
the hemagglutinin (H) and the fusion (F) glycoproteins. The matrix (M) lines 
the inner surface of the envelope and associates with the cytoplasmic tails 
of the H and F proteins as well as the viral core particle or nucleocapsid.  
The viral RNA genome is encapsidated by the nucleoprotein (N) to 
form a helical ribonucleocapsid (RNP) that is the substrate for both 
transcription and replication. These latter activities are carried out by the 
RNA dependent RNA polymerase (RdRp) that is composed of the large (L) 
protein and of the phosphoprotein (P). A schematic representation of a MV 
particle is shown in Fig. 1 (A). 
The 15,894 nucleotide long MV genome contains six genes, coding 
for eight proteins in the order 3’-N-P/V/C-M-F-H-L-5’. The P gene uses 
overlapping reading frames to code for three proteins, P, V and C. These 
genes are flanked by a 3’ extracistronic region, the leader, and a 5’ 
extracistronic region, the trailer, that are essential for transcription and 
replication Fig. 1 (B).  
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Figure 1. (A) Schematic diagram of a polyploid MV particle containing 
three genomes. The viral nucleocapsid (N), phosphoprotein (P), 
polymerase (large, L), matrix (M), fusion (F), and hemagglutinin (H) proteins 
are indicated with different symbols. (B) Diagram of the MV antigenome 
(plus strand). The coding regions of MV genes are represented by arrow-
shaped boxes. 
M 
H 
(tetramer) 
F 
(trimer) 
N 
L 
P 
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N P/V/C M H LF
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1.4.1.1. Nucleocapsid protein 
The nucleocapsid messenger RNA, the first to be transcribed, codes 
for the N protein (525 aa), the most abundant viral protein. The N protein 
is an RNA-binding protein that encapsidates the full length viral (-) sense 
genomic and (+) sense antigenomic RNAs within a helical nucleocapsid 
template. The helical nucleocapsid rather than the free genome RNA is the 
template for all the RNA synthesis (95). Each N protein coats 6 nucleotides, 
the so called “rule of six” i.e. their genome must be of polyhexameric 
length to efficiently replicate (20). The binding of N to RNA to form a helical 
structure is thought to have several functions, including protection from 
nuclease digestion and providing interaction sites for assembly of 
nucleocapsids into budding virions (95). 
Biochemical and mutational studies have identified two structural 
regions in the N protein: N core, a conserved N-terminal domain and a non 
conserved N tail, C-terminal. The N core has ~ 400 aa and is essential for 
self assembly of N with RNA, RNA binding and for RNA replication. The C-
terminal N tail region is ~ 100 aa and interacts with a C-terminal domain of 
P protein. In infected cells, two forms of N exist: a monomeric form 
(referred to as N
0
) and an assembled form (referred to as N
NUC
) (55). In its 
assembled form, N interacts with P and the polymerase complex (L–P), 
which is essential to RNA synthesis by the viral polymerase (18). In its 
monomeric form, it is responsible for the encapsidation of the nascent RNA 
chain during genome and antigenome replication. During virus assembly, N 
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interacts with the M protein. Finally, it interacts with cellular factors, 
including cytoskeleton components. 
During the course of infection, polymerase activity changes from 
transcription to replication. By analogy with studies made in vesicular 
stomatitis virus (VSV) (14), the intracellular concentration of unassembled 
N is thought to be a major factor controlling the rates of transcription and 
replication from the genome templates.  
 
1.4.1.2. P, V, and C proteins 
The P protein, 507 aa, plays multiple roles in both transcription and 
replication. It is an essential component of the viral polymerase and binds 
to the nucleocapsid tethering the polymerase complex L-P to the 
nucleocapsid (N
NUC
) template (79, 88). It is a modular protein consisting of 
at least 2 domains: an N-terminal domain (PNT) and a C-terminal domain 
(PCT). The acidic and highly phosphorylated N-terminal domain includes aa 
1 to 230 and is poorly conserved. It is the assembly module required to 
chaperone unassembled N protein as a P-N complex during the nascent 
chain assembly step of genome replication (73, 173). The C-terminal 
domain (aa 231-507) is well conserved; it represents the polymerase 
cofactor module and mediates binding of L to the N-RNA template. 
In addition to the P protein, the P gene gives rise to two other 
polypeptides by means of using overlapping reading frames (ORF) on a 
single transcript. The C ORF is accessed by translational choice using an 
initiator methionine codon 19 nucleotides downstream from that of P (10). 
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In contrast, the V protein shares the initiator methionine and the amino-
terminal 231 aa of the P protein but has a different C-terminal region. An 
extra non-template-directed guanosine (G) residue at position 751 is added 
following three Gs by a process known as RNA editing or pseudotemplated 
transcription (25). This nucleotide addition results in a shift of the 
translational reading frame into an alternative reading frame and hence a 
different C-terminal region. The last 276 aa normally encoded by the P 
mRNA are replaced with a cyteine-rich domain of 68 aa (25) that has zinc-
binding properties (100). 
The N-terminal region of the P protein, as the collinear region of the 
V protein, binds to STAT1, with the Tyr110 residue playing a key role in this 
interaction (19, 38, 128). The C and V proteins play a role in the regulation 
of transcription and replication and are not found in the virions (101, 188). 
The V and C proteins have been analyzed for their ability to modulate 
either interferon (IFN) type I or its signaling pathways. The C protein is 
implicated in inhibition of IFNAR downstream signaling (166), modulation 
of the viral polymerase activity, inhibition of cell death and of inflammatory 
responses (9, 150, 185). Other reports show that V protein can counteract 
the interferon antiviral activity and can inhibit the inflammatory response 
in infected peripheral blood monocytic cells of experimentally infected 
monkeys (36). 
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1.4.1.3. Matrix protein 
The M protein, coded by the third gene, is a basic protein and 
underlies the viral lipid bilayer. M is thought to play a crucial role in the 
assembly of progeny virus by interacting with the RNP (70, 71). In addition, 
M interacts with the cytoplasmic tails of H and F proteins (23, 174) and 
drives the apical assembly of MV leading to the release of infectious 
particles early after infection (116). Abrogation of M function dramatically 
alters the assembly of MV (12, 22). M inactivation or failure to associate 
with budding structures or with the viral nucleocapsid is likely to be a 
factor responsible for MV persistent infection where release fails to occur. 
In SSPE the M protein is either absent (12) or, when present, is not 
associated with budding structures in cultivated cells and is not able to 
bind to viral nucleocapsid in vitro (27, 70, 71). In addition, the M protein 
controls fusion function of the viral envelope glycoproteins (22). A 
genetically engineered recombinant MV that lacks M shows increased cell-
to-cell fusion and decreased production of infectious particles (22). More 
recently, Tahara et al. (179), identified two substitutions in the M protein 
of attenuated MV, P64S and E89K, that, by allowing a strong interaction 
with the cytoplasmic tail of H, enhanced the assembly of infections 
particles in Vero cells but inhibited MV signaling lymphocytic activation 
molecule (SLAM)-dependent cell-cell fusion, reducing viral growth in B 
lymphoid cells. By modulating viral growth, M protein may partly account 
for the attenuation of MV attenuated strains (178, 179).  
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1.4.1.4. Fusion protein 
The F protein mediates viral entry with release of the RNP into the 
cytoplasm by fusion between the virion envelope and the host cell plasma 
membrane at neutral pH. Later in infection, the F protein, expressed at the 
cell surface membrane, can mediate fusion with neighboring cells to form 
syncytia (giant multinucleated cells), a cytopathic effect caused by MV that 
is an alternative mechanism of viral spread. 
The fusion protein, 533 aa, is a type I transmembrane glycoprotein 
(151). MV F protein includes an N terminal cleavable signal sequence that 
targets the nascent polypeptide chain synthesis to the membrane of the 
endoplasmic reticulum (ER). At the C terminus, a hydrophobic stop-transfer 
domain anchors the protein in the membrane leaving a short 33 aa 
cytoplasmic tail. 
F is synthesized as an inactive precursor, F0 and gains its fusogenic 
activity by cleavage by the ubiquitous intracellular protease furin, localized 
in the trans Golgi network (15, 201). Proteolytic cleavage results in a 
disulfide-linked fusion competent F protein that consists in a 
transmembrane F1 and a membrane distal subunit F2. F1 contains a stretch 
of hydrophobic aa at the N-terminus constituting the fusion peptide that is 
inserted into the target membrane when fusion occurs. The F2 subunit 
contains all three N-linked glycans that have a role in proteolytic cleavage, 
stability and transport to the cell surface (77, 193). 
The MV F-protein is classified as a class I fusion protein (94). Class I 
fusion proteins mediate membrane fusion by coupling irreversible protein 
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refolding to membrane juxtaposition. This is accomplished by discrete 
conformational changes of a metastable F protein structure to a lower 
energy structure. The cleavage of F0 into F1-F2 primes the protein for 
membrane fusion. Activation of the F-protein results in the insertion of the 
fusion peptide located in the F1 subunit into the target membrane. This is 
followed by dramatic conformational rearrangements of the F trimer and 
results in juxtaposition of the target and donor membranes (205). As the F-
protein goes from a high-energy metastable structure to a low-energy 
post-fusion structure, this eventually leads to the formation of a fusion 
pore through which the RNP complex enters the cell (95). 
 
1.4.1.5. Hemagglutinin protein 
The H protein is the receptor attachment protein and is an 
important determinant of cellular tropism. It is a 617 aa type II 
transmembrane glycoprotein which is comprised of a N-terminal 
cytoplasmic tail of 34 aa followed by a membrane-spanning domain and an 
extracellular membrane - proximal stalk region connected to a C-terminal 
receptor-binding head domain (3). Receptor-binding residues have been 
mapped to this head domain (76, 99, 121, 177, 198). While other 
paramyxovirus attachment proteins are globular, MV H protein exhibits a 
cube shaped structure. A significant area of the H protein is covered with 
N-linked oligosacharides which makes it unavailable for receptor 
interaction (67). In contrast to other paramyxovirus attachment proteins, H 
only forms dimers (142). The two H protein molecules making up the 
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homodimer are highly tilted with respect to each other. This has further 
consequences for receptor specific fusion. 
The first step in the fusion process is binding of H to its receptor. On 
binding ligand, the H protein undergoes its own conformational change, 
which in turn triggers a conformational change in F to release the fusion 
peptide. The H protein of the Edmonston strain has five predicted N-linked 
glycosylation sites; the first four of these sites are used. Glycosylation is 
necessary for proper folding, antigenicity, dimerization, and export of H 
from the Golgi (78).  
 
1.4.1.6. Polymerase (large) 
The L protein is the least abundant but the largest protein (240 
KDa). The L gene codes for the paramyxovirus RdRp which possess all 
enzymatic activities necessary to synthesize mRNA, like nucleotide 
polymerization, 5’ end mRNA capping and methylation, and 
polyadenylation of mRNA (57, 69, 124). L adds poly-A tails to nascent viral 
mRNAs cotranscriptionally by stuttering on a stretch of U residues 
occurring at the end of each viral gene. 
L includes six highly conserved domains that were identified by 
sequence comparisons. The exact role of several domains is not clear but 
mutations in some of these domains resulted in L proteins that although 
were able to transcribe viral mRNA were defective in RNA replication (143, 
169).  
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L binding to the viral P protein is mapped to the N-terminal 408 aa 
of L (73) and this interaction confers stability to L (65, 72). Within the L-P 
complex, the P protein bridges the L polymerase to the nucleocapsid 
template. The L protein besides interacting with P can interact with host 
cell proteins (172). 
 
1.4.2. Measles virus life cycle 
MV contains nonsegmented single-stranded RNA genome of 
negative polarity and replication occurs entirely in the cytoplasm. An 
overview of the life cycle of MV is depicted in Fig. 2. The H protein contacts 
the receptors whereas the F protein mediates fusion. After the viral 
membrane fuses with the cellular plasma membrane at the neutral pH, the 
helical nucleocapsids are released into the cytoplasm. The uncoating 
process takes place by disrupting of the M-N contacts.  
Early in virus infection, before the viral translation products 
accumulate to high levels, the viral RdRp activity is restricted to the 
production of a leader RNA and mRNAs from the incoming virion 
nucleocapsid in what is called primary transcription. At later times 
following infection, this input RNP is used as a template to produce (+) 
sense antigenomes which are in turn used as templates to produce new (-) 
sense genomic RNA. After primary transcription and translation, when 
abundant progeny genomes have been produced, they can serve as 
additional templates in what is called the secondary transcription to 
produce much higher levels of viral mRNA transcripts (95). The processive 
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viral polymerase transcribes the N-encapsidated genome RNA into 5’ 
capped and 3’ polyadenylated mRNAs. Beginning at the 3’ end of the 
genome, the polymerase transcribes the genes in a sequential and polar 
manner by terminating and reinitiating at each end of the gene junctions. 
This sequential “stop-start” mechanism continues across the viral genome 
in a 3’ to 5’ direction. Polyadenylation occurs by reiterative copying of four 
to seven uridylates in the gene end sequence, followed by release of the 
mRNA. Initiation and capping of the downstream mRNA is specific by the 
gene-start sequence following the short intergenic region. The RdRp 
sometimes fails to reinitiate and this leads to a gradient of mRNA 
abundance that decreases according to the distance from the genome 
3’end with N mRNA being the most abundant and the L mRNA the least 
abundant (26). 
 Paramyxovirus particles are formed by a budding process. Buds 
emerge from the plasma membrane in locations where the viral 
components are assembled. Assembly is thought to require coordinated 
localization of multiple virus proteins that are preferently incorporated into 
nascent viral particles, whereas most of the host proteins are excluded. The 
assembly of the envelope is at the cell surface and in polarized epithelial 
cells MV egress from the apical surface. 
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Figure 2. Measles virus life cicle. The top of the figure illustrates an 
incoming virion which fuses with the cell plasma membrane followed by 
release of the helical nucleocapsid in the cytoplasm. Viral mRNAs are 
indicated by lines and 5’ mRNA cap is represented by a filled circle whereas 
3’ poly A tail by an An. Genome replication carried out by the N-P-L 
complex and primary and secondary transcription carried out by P-L 
complex are represented in solid lines. Intracellular transport of RNP and M 
protein to the plasma membrane and of F and H proteins from the ER to 
Golgi to the plasma membrane is indicated with dotted lines. (Adapted 
from Lamb, R.A. and Parks, G.D., Fields Virology, 2007). 
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1.4.3. Measles virus receptors 
MV was isolated first by Enders and his team in 1954 by inoculating 
blood of David Edmonston, a child with measles, onto a primary culture of 
human kidney cells (42). However, it was not until 1993 that the first 
cellular receptor for MV was identified. Two independent groups reported 
that laboratory adapted strains of MV could enter host cells via the 
ubiquitous regulator of complement activation membrane cofactor protein 
(MCP; CD46) (39, 119). The observation that strains isolated in B95a cells or 
human B-cell lines grow inefficiently in cells susceptible to the attenuated 
strain, lead to hypothesize that these strains might use other cellular 
receptor. Indeed, a few years later, Tatsuo et al. (186) using a functional 
expression cloning approach, showed that a cDNA clone could render a 
resistant cell line susceptible to a B95a cell-isolated MV. This cDNA was 
shown to encode human SLAM or signaling lymphocytic activation 
molecule, expressed on several immune cells and first described as 
involved in T cell activation (29, 170). Other authors confirmed these 
findings (44, 75). 
MV is able to infect several tissues and cells that do not express any 
of the known receptors, suggesting that additional receptors may still await 
identification. Indeed, recent studies showed that human polarized 
epithelial cell lines support MV entry, replication, and cytopathic effect 
independent of SLAM and CD46 (99, 177). 
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1.4.3.1. CD46 
CD46 (MCP) was identified by several research groups in the 
eighties as a cell surface molecule with a broad double pattern on SDS-
PAGE and later denominated CD46. Further studies characterized this 
glycoprotein belonging to the regulators of complement activation family 
with the function to protect host cells from complement mediated attack 
(102). CD46 protects the cells from complement mediated damage by 
serving as a cofactor for the factor I-mediated cleavage of C3b to C3bi and 
C4b to C4c and C4d, preventing the C3b and C4b forming the C3/C5 
convertase required for complement regulatory function (102). 
CD46 is a cell surface, type I transmembrane glycoprotein of 57-67 
kDa encoded by a single gene that is ~ 50 kb long and comprises 14 exons. 
The N-terminal region of the CD46 protein consists of four short consensus 
repeats (SCR) also named complement control protein repeats (CCPs) (Fig. 
3). These SCR are domains of about 60 aa. SCR 1, 2 and 4 are N-
glycosylated; N-glycosylation of SCR 2 is essential for its function as MV 
receptor (105). The SCR are followed by one or two serine-threonine-
proline (STP) rich regions, sites of O-glycosylation. Following the STP region 
are 12 aa of unknown function, a transmembrane domain and one of two 
cytoplasmic tails (CYT-1 or CYT-2).  
CD46 is expressed as four predominant isoforms. These isoforms 
are the result of the alternative splicing of CD46 gene and differ in the 
presence of one (C) or two (BC) STP region and the 16 amino acid (CYT-1) 
or 23 amino acid (CYT-2) CYT domains (102). These isoforms are termed 
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STP-BC1, STP-BC2, STP-C1, and STP-C2 and migrate on a SDS-PAGE as two 
band pattern with molecular weight (MW) of 62,000-67,000 (STP-BC1 and 
STP-BC2 isoforms) and 54,000-60,000 (STP-C1 and STP-C2 isoforms) (102). 
All isoforms can serve as receptors for MV (52, 106). Functional studies 
mapped the C3b/C4b-regulatory activity on SCR2-4 (2, 80) whereas MV H 
protein binding site resides within SCR 1 and 2 (17, 37). 
CD46 is expressed on almost all human nucleated cells (165). Three 
patterns of expression, differing in the ratio of expression of the four main 
isoforms, are recognized in the population: most individuals (65%) express 
the STP-BC1/2 forms, 29% express both forms in equal quantities and 6% 
express the STP-C1/2 forms (102). 
Besides serving as a cellular receptor for MV, CD46 is used as a 
receptor and port of entry by other human pathogens. A number of 
pathogenic bacteria including Streptococcus pyogenes and Neisseria 
meningitides and gonorrhoeae bind to CD46 and different serotypes of 
adenovirus and herpesvirus 6 utilize CD46 as cellular receptor (24). 
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Figure 3. Structures of MV receptors SLAM (left) and CD46 (right). SLAM, a 
member of the CD2 subset of the immunoglobulin superfamily, regulates 
synthesis of T helper 2 cytokines by T cells. The extracellular domain is 
composed of a variable (V) and a constant (C2) domains. All MV strains 
bind to the V domain of SLAM. CD46, a regulator of complement activation, 
has four SCR modules in the extracellular domain. The vaccine strains of 
MV interact with SCR1 and 2, whereas SCR 2 and 4 interact with 
complement C3b and C4b. APC: antigen presenting cell. (Adapted from 
Yanagi, et al., Measles virus: cellular receptors, tropism and pathogenesis. 
J. Gen. Virol., 2006). 
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1.4.3.2. SLAM  
The lingering question of the relevance of a ubiquitous receptor for 
MV pathogenesis was answered when in 2000, the signaling lymphocyte 
activation molecule (SLAM; CD150) was identified as the cellular receptor 
for clinical isolates of MV (44, 75, 186). Importantly, attenuated strains of 
MV can use SLAM as a cellular receptor, in addition to CD46 (45, 132). 
SLAM is a 70 kDa membrane glycoprotein that belongs to the CD2 
subset of immunoglobulin gene superfamily and has two extracellular 
immunoglobulin domains (V and C2) (Fig. 3). The MV H protein interacts 
with the N-terminal V domain of SLAM and this domain is necessary and 
sufficient to allow MV entry (133). Although mouse SLAM has 60% 
sequence identity to human SLAM and similar function, it cannot act as MV 
receptor. 
SLAM can interact with another SLAM molecule present on a 
neighbor cell (Fig. 3) (107). Its cytoplasmic domain contains three tyrosine 
residues that are surrounded by SH2 domain-binding sequences. SLAM 
associates intracellularly with SH2 domain-containg molecules such as the 
SLAM-associated protein (SAP), protein tyrosine phosphatase SHP2 and, 
inositol phophatase SHIP (159). Ligation of SLAM on T cells leads to its 
binding to SAP, which then recruits and activates FynT, resulting in tyrosine 
phosphorylation of SLAM. This triggers the recruitment of multiple players 
involved in SLAM signaling (96). This leads to the production of T helper 2 
(Th2) cytokines such as IL-4 and IL-13 (43, 104). SLAM regulates the 
production of IL-12, tumor necrosis factor-α (TNF-α) and nitric oxide by 
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macrophages (32, 200). In addition, SLAM may induce B cell proliferation 
and immunoglobulin (Ig) synthesis (146).  
SLAM is expressed on immature thymocytes, on memory T cells, 
and is readily induced on B and T cells following activation (7, 29, 170). 
According to the same authors, SLAM is not detected on granulocytes, 
monocytes and cells from non lymphoid organs (7, 29, 170). However, 
SLAM expression on monocytes was readily induced after stimulation with 
mitogens or after MV infection (109). Furthermore, SLAM was detected in 
murine macrophages following activation with LPS (74). Mature dendritic 
cells, but not immature ones express SLAM (13, 92, 125, 144). Distribution 
of this receptor overlaps with sensitivity of different cell types to wild type 
MV infection and better explains the immunosuppressive characteristics of 
the virus. 
Besides MV, other morbillivirus like canine distemper virus (CDV) 
and rinderpest virus use SLAM (canine and bovine respectively) as their 
cellular receptor (187).  
 
1.4.3.3. Other receptors 
MV spreads systemically and eventually it infects epithelial tissues 
of several organs (108, 157). However these tissues do not express SLAM; 
CD46, which is ubiquitously expressed, does not support infection by wild 
type MV. This implies that MV may use another receptor (204). The 
identification of a putative receptor on epithelial cells still remains elusive 
but two groups mapped the residues of the MV attachment protein 
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sustaining epithelial cell receptor mediated cell fusion and showed that the 
receptor binding site on the H-protein required to infect epithelial cells 
differs from the binding sites for CD46 and SLAM (99, 177). Moreover, 
results from these two groups suggest that the epithelial receptor may be a 
molecule related with tight junctions and located on the basolateral 
surface of the epithelial cells (Fig. 4, top left scheme). Infected immune 
cells would infect the epithelial cells through this basolateral molecule and 
the virus would initiate replication in epithelial cells. The active release of 
infectious viral particles in the airways would explain the high infectious 
nature of MV.  
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Immune cells
 
 
Figure 4. MV is transmitted by respiratory aerosol droplets containing 
MV particles and initial replication takes place in immune cells in the 
upper respiratory tract using SLAM receptor (right drawing). Infected 
immune cells enter the lymphatic or blood circulation and propagate in 
the lymphatic organs throughout the body (bottom drawing). MV 
infected immune cells or released viral particles infect epithelia of 
several mucosal organs trough the use of a putative epithelial receptor. 
Infected epithelial cells release viruses in the airways to achieve 
transmission and completing the infectious cycle (left drawing). 
(Adapted from Navaratnarajah, C. et al., Measles virus glycoprotein 
complex assembly, receptor attachment, and cell entry. Curr. Topics 
Microbiol. Immunol., 2009). 
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1.5. Measles virus pathogenesis 
Measles is typically a childhood acute disease characterized by 
fever, cough, conjunctivitis and a generalized maculopapular rash. Clinical 
symptoms appear after a period of incubation of 10-14 days and this is 
accompanied by a transient but profound immunosuppression. Recovery is 
accompanied by lifelong protective immunity to re-infection (59).  
 
1.5.1. Measles virus entry and spread 
MV is transmitted by aerosol droplets and until recently initial 
replication was believed to occur in the epithelia of the respiratory tract 
followed by viremia mediated by infected monocytes or macrophages (47, 
59). From the respiratory tract the virus spreads to the lymphatic tissues, 
where viral amplification occurs and then to other organs like skin, 
conjunctiva, kidney, lung, gastrointestinal tract, respiratory and genital 
mucosa, and the liver (152).  
A classical study of the infection of CDV, a related morbillivirus of 
dogs showed that the virus was present in the bronchial LN and tonsils 1 
day p.i. and it appeared in the lungs only 3 to 6 days later (4). Moreover, in 
a ferret model of CDV pathogenesis (194, 195) primary replication occurred 
in the lymphatic tissue of the oral cavity and of the respiratory tract. Viral 
replication in epithelial cells, sustaining lung and bladder invasion, was 
found only in later stages of infection (194). In addition, experimentally 
infection of macaques with a recombinant wild type MV expressing GFP 
resulted in predominant infection of SLAM positive lymphocytes and DCs 
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and an occasional infection of epithelial cells at later stages of infection 
(34). Based on this, the initial target cells for MV infection are still not well 
characterized. Fig. 4 illustrates the proposed model of MV infection and 
transmission based on the recent findings. 
 
1.5.2. Immune response to measles virus infection 
MV infection induces an efficient immune response leading to viral 
clearance and long life immunity against re-infections. It gives rise to a non-
specific activation of the immune system characterized by a spontaneous 
proliferation of peripheral blood mononuclear cells (PBMC) and an 
upregulation of activation associated cell surface markers. Along with this 
immune activation, MV induces a transient but severe immunosuppression 
which increases the susceptibility to opportunistic secondary bacterial and 
viral infections, mainly in immunocompromised individuals. 
Different components of the immune response are elicited by MV 
infection. The first immune response to be activated by MV infection is the 
innate immune response followed by the development of MV specific 
adaptive immune responses.  
 
1.5.2.1. Innate immunity 
Innate immunity plays a major role in establishment of adaptive 
immune responses. The innate immune system recognizes viral 
components through pattern-recognition receptors (PRRs). This recognition 
triggers a signal transduction cascade that activates transcriptional 
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responses that culminates in the production of proinflamatory cytokines, 
interferons, and TNF-α. Two classes of PRRs have been described in innate 
immune cells and involved in the recognition of MV, namely Toll-like 
receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors 
(RLRs). Activation of TLRs and RLRs is important for the production of type I 
interferons and cytokines. Binding of type I IFNs to cognate receptors on 
the cell surface triggers JAK/STAT signaling pathway leading to a formation 
of IFN-stimulated gene factor 3 (ISGF3) complex comprised of STAT1, 
STAT2 and IRF9. The ISGF3 complex translocates into the nucleus and 
activates the IFN-stimulated response element (ISRE)-mediated gene 
transcription gene resulting in synthesis of numerous proteins to establish 
the antiviral state.  
MV has developed ways to circumvent the host innate immune 
response. MV was shown to inhibit signaling for both type I IFN induction 
and JAK/STAT signaling pathway. MV is able to shut down IFN-α induction 
in response to TLR7 and TLR9 ligands (160) and MV V protein can block 
melanoma differentiation-associated gene 5 (MDA-5) mediated IFN 
induction pathway (117). Several other reports show that the V, C, and P 
proteins are able to block the JAK/STAT signaling pathway (19, 38, 49, 123, 
128, 134, 149, 166, 183, 206). 
 
1.5.2.2. Humoral immunity 
MV specific neutralizing antibodies play a key role in preventing re-
infection after natural exposure to MV. However, the role of antibodies in 
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viral clearance remains unclear since individuals with deficient antibody 
production are still able to resolve the infection, and depletion of B cells in 
experimentally infected monkeys does not affect viral clearance (138). 
Nevertheless, it was reported that failure to mount an adequate antibody 
response to MV infection carries a poor prognosis in children (203). 
Antibodies are initially detected at the onset of the rash. During 
acute measles IgM are predominant and this is followed by a switch to IgG2 
and IgG3, whereas during recovery IgG3 seems to decrease and IgG1 and 
IgG4 increase (59). Antibodies are produced to all MV proteins, with 
antibodies to the N protein being initially most abundant. Absence of this 
antibody is an indicator of seronegativity. The majority of neutralizing 
antibodies are specific for the H protein although antibodies to F 
contribute to virus neutralization as well (145). MV specific neutralizing 
antibodies binding to infected cells alters intracellular virus replication and 
this way may contribute to control of infection (50, 54). 
 
1.5.2.3. Cellular immunity  
The role of cellular immunity in recovery from MV infection has 
been appreciated from humans presenting immune abnormalities. Children 
with impaired T cell immunity frequently die of progressive measles while 
infection is cleared in individuals with agammaglobulinaemia (138, 140). In 
addition, monkeys depleted of CD8+ T cells and challenged with wild type 
MV had more severe rash, higher viral load in the blood and a prolonged 
time to clear infection (139).  
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The cellular immune response is present at the onset of the rash. 
Expansion of cytotoxic CD8 T cells and production of IFN-γ were observed 
after MV infection and the establishment of CD8 T cell memory as well (81, 
82, 118, 190). In addition, CD4 T responses are activated during MV 
infection and the synthesis of cytokines is increased. 
Acute measles generates a Th1 response profile, characterized by 
IFN-γ and IL-2 production while the recovery phase is characterized by a 
skew towards a Th2 response resulting in high levels of IL-4 and IL-10 and 
low IFN-γ levels. The cytokine response after MV infection influences 
disease outcome. In the acute phase of measles, IFN-γ, neopterin and IL-2 
rise whereas at the time of the rash there is an increase in IL-2, in soluble 
CD8 and CD4. In the recovery phase, when the rash starts to fade, there is 
an elevation in the levels of IL-4, IL-10 and IL-13 persisting for several 
weeks (61, 111).  
 
1.5.3. Measles virus-induced immunosuppression  
MV infection of immunocompetent host causes a virus-specific 
immune response that clears infection and provides lifelong immunity. 
However, concomitantly, MV is responsible for a generalized 
immunosuppression that dampens immune responses to other pathogens. 
Immunosuppression induced by MV is characterized by: abnormal cytokine 
production, with an imbalance towards a Th2 response resulting in an 
impaired cellular immune response to new antigens (60); suppression of 
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lymphoproliferative responses to mitogens and a marked lymphopenia 
(156). 
The mechanisms underlying immunosuppression induced by MV 
are complex. Apoptosis (46), unidentified soluble mediators produced by 
infected cells causing inhibition of proliferation of B and T cells (175, 199), 
impaired dendritic cell function, lymphocyte depletion (129, 130) and 
interleukin 12 downregulation (6, 87) may account for this immunological 
abnormality.  
 
1.6. Mouse models for the study of measles pathogenesis: SLAM 
transgenic mice   
Studies of MV pathogenesis have been hindered by the lack of 
suitable animal models. Humans are the only natural host for MV. Non-
human primates have been successfully infected with MV and can 
reproduce many aspects of the disease, however these are scarce and 
costly and their use raises ethical questions. Since viral tropism is 
determined by the pattern of expression of virus specific cellular receptors, 
the discovery of the human MV receptors, CD46 and SLAM, has opened the 
possibility of the development of transgenic mice susceptible to MV 
infection. Several transgenic mice lines have been developed expressing 
one or both receptors. The different outcome obtained with these models 
reflects the use of different promoters, composition and integration site of 
the transgenic construct.  
General Introduction 
 
33 
 
Since the identification of human SLAM as the receptor for both 
wild type and attenuated strains of MV several mice lines expressing SLAM 
have been developed. Table 2 refers to the most relevant SLAM transgenic 
lines and the outcome of infection.  
Table 2. Comparison of SLAM transgenic mouse models of MV infection. 
(adapted from Sellin C.I. and Horvat B., Current animal models: transgenic 
animal models for the study of measles pathogenesis. Curr. Topics 
Microbiol. Immunol., 2009). 
 
 
Model Pattern of 
expression  
Immunological 
status 
Clinical signs and 
pathology following 
infection 
Lck-CD150 
 (Hahm et al. 2003) 
T 
lymphocytes 
 
Immunocompetent Infection of thymocytes 
of neonates infected IP 
Ex vivo inhibition of T 
cell proliferation  
CD11c-CD150 
 (Hahm et al. 2004) 
Splenic and 
bone 
marrow 
derived 
dendritic 
cells 
 
Immunocompetent Infection of 2 to 5% 
dendritic cells after i.v. 
inoculation 
CD150Ge x STAT1-ko 
 (Welstead et al. 
2005) 
Human-like 
expression 
Immunodeficient IN and IP infection of 
lymph nodes, spleen 
and thymus  
Knock-in CD150 x 
IFNAR-ko 
 (Ohno et al. 2007) 
Human-like 
expression 
Immunodeficient IN and IP infection of 
spleen and lymph 
nodes, 
immunosuppression 
CD46Ge x CD150Ge 
x IFNAR-ko 
 (Shingai et al. 2005) 
Human-like 
expression 
Immunodeficient Infection of dendritic 
cells in lymph nodes 
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The Lck-CD150 transgenic mouse was the first CD150 transgenic 
mouse to be generated. Human SLAM was expressed under the control of 
Lck promoter and thus restricted to T lymphocytes from thymus, spleen 
and blood. Spleen lymphocytes were susceptible to in vitro infection with 
MV wild type and vaccine strains and infection correlated with the amount 
of SLAM expressed in these cells. In addition, MV infection of T cells 
expressing hSLAM inhibited their proliferation and rendered them 
unresponsive to mitogen. Intraperitoneal infection of newborns resulted in 
infection of SLAM expressing thymocytes (62).  
To test the role of infection of DC on MV-induced 
immunosuppression a transgenic mouse was generated where hSLAM is 
expressed under a CD11c specific promoter; hSLAM expression was 
restricted to splenic and bone marrow derived dendritic cells (63). These 
mice were also used to study the effect of MV infection on the ability of 
dendritic cells to induce IL-12 synthesis via toll-like receptor signaling. 
Engagement of TLR-4 on MV infected DCs but not TLR-2, 3, 7 or 9 resulted 
in defective IL-12 production. Furthermore, interaction of MV H with 
hSLAM, but not the MV V and C proteins, influenced this inhibition. These 
results suggested that MV, by altering DC function, renders them 
unresponsive to secondary pathogens via TLR4 (64). 
Another transgenic mouse was generated expressing the complete 
human gene through the use of the human’s gene endogenous promoter 
(202). Human SLAM expression profile was equivalent to expression in 
humans; expression of SLAM was detected on activated B and T 
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lymphocytes from spleen and on activated bone marrow derived DC. 
Intranasal infection of these mice with a wild type MV resulted in transient 
infection of the nasal associated lymphoid tissue 6 days after inoculation. 
To improve efficiency of MV infection these mice were then bred into a 
STAT-1 deficient background. Four to six days upon IN or IP infection, 
mRNA of MV was detected on thymus, spleen, and lymph nodes of these 
mice. However, these mice did not show clinical signs of disease. 
Abnormally number of neutrophils and natural killer cells were shown to 
be responsible for the splenomegaly observed after IP infection. Crossing 
this parental strain, SLAMGe mice (202), with Ifnar
ko
-CD46Ge mice (113) 
resulted in the strain Ifnar
ko
-SLAMGe mice used in our studies, further 
showed in Chapters 2, 3 and 4. 
As the V domain of human SLAM is necessary and sufficient for MV 
binding to CD150 receptor (133), Ohno et al (127) used a knock-in 
approach to establish a mouse model where the V domain of mouse SLAM 
was replaced by that of human SLAM by homologous recombination in 
embryonic stem cells. In these mice SLAM had an expected human-like 
tissue specificity of expression and retained normal function. Splenocytes 
from these mice sustained productive infection when infected in vitro. 
However, in vivo infection was limited. To increase efficiency of infection 
these mice were crossed on an IFNAR
ko
 background. Following IN infection 
virus spread to the draining lymph nodes of the respiratory tract and to 
other lymphatic tissues throughout the body. In addition, after IP infection, 
splenocytes failed to proliferate when stimulated with concanavalin A. 
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Thus, infection of these mice reproduces MV lymphotropism and 
immunosuppression as in humans and might be relevant for the study of 
MV immunopathology when production of type I interferon is not relevant.  
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Aims 
The aim of this thesis is to study MV receptor-host interactions and 
assess the consequences of these interactions for MV spread and 
pathogenesis. Towards this we characterized MV infection in a transgenic 
mouse expressing the cellular receptor for MV, SLAM (CD150). First, we 
characterized the tissue specificity of SLAM expression in these mice and 
assessed the spread of wild type MV in lymphoid and non-lymphoid organs 
of mice that are expressing human SLAM (Chapter 2). Second, we aimed at 
identifying the initial cellular target cells of MV infection after contagion 
(Chapter 3) and third, to gain insight on the mechanisms of MV attenuation 
we characterized the spread of an attenuated and a wild type strains of MV 
in the lymphatic system in the transgenic mice expressing human SLAM 
(Chapter 4). 
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CHAPTER 2 
Measles virus infection of transgenic mice expressing human 
signaling lymphocytic activation molecule (SLAM, CD150) 
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Abstract 
 We bred a transgenic mouse expressing SLAM with human like 
tissue specificity in an interferon type I deficient background (Ifnar
ko
) to 
allow more extensive measles virus (MV) replication. We obtained B cells 
from the spleen and T cells from the thymus of these Ifnar
ko
-SLAMGe mice 
and documented an increase in human SLAM (hSLAM) expression after 
activation of these cells. Macrophages from the bone marrow of these 
mice expressed hSLAM twenty four hours after lipopolysaccharide (LPS) 
activation. Furthermore we showed that ex vivo inoculation of 
macrophages with a MV expressing green fluorescent protein, wtMVgreen, 
resulted in infection in a receptor-dependent manner. To assess the spread 
of MV in vivo, we infected these mice intranasally or intraperitoneally with 
a virus expressing the reporter protein chloramphenicol acetyltransferase 
(CAT), from an additional transcription unit downstream the hemagglutinin 
gene, here named wtMVCAT. Three and six days after inoculation, the lungs, 
thymus and spleen were collected and the CAT activity was assessed in 
homogenates of these tissues. Intranasal (IN) inoculation resulted in viral 
replication in the airways. Later the virus spread to the lymphatic system 
with involvement of the spleen. MV replication was more efficient in the 
spleen and less efficient in the lungs after intraperitoneal (IP) inoculation. 
Thus, Ifnar
ko
-SLAMGe mice seem particularly useful in the study of the 
early phases of MV infection and dissemination. 
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Introduction 
Despite eradication efforts and the availability of an inexpensive 
and safe vaccine, measles is still included in the group of five conditions 
that make up to 70% of deaths in children younger than 5 years (41). 
As humans are the only natural host for MV, a complete 
understanding of many aspects of MV infection and pathogenesis is 
hampered by the lack of a suitable animal model. MV is pathogenic only for 
non human primates but these are scarce and costly and ethical questions 
can be raised. Mice, for their availability and low cost, constitute an 
alternative model to study MV pathogenesis. However, MV replication in 
mice is inefficient and occurs only after intracranial inoculation of brain-
adapted strains. The lack of human receptors for MV on mice presents a 
major obstacle to their use and has motivated the development of 
transgenic mice expressing MV receptors with human like tissue specificity 
as recently reviewed (164). 
Several transgenic mice have been generated in the last decade to 
study MV infection and pathogenesis. Initial studies of MV infections were 
conducted in transgenic mice expressing human CD46 (MCP, human 
membrane cofactor protein). CD46 is the cellular receptor for MV 
attenuated strains (39, 119). These studies reported inefficient and short-
lived dissemination of an attenuated strain of MV. To overcome these 
limitations CD46 transgenic mice were bred into a type I interferon 
receptor knock out (IFNAR
ko
) background (112, 113). 
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CD46 transgenic mice present a major limitation as they only 
support infection by the vaccine and laboratory adapted strains of MV; the 
identification of SLAM (CD150, signaling lymphocyte activation molecule) 
as a receptor for both wild type and laboratory MV strains (75, 186) 
opened new perspectives in the generation of transgenic mice to study the 
pathogenesis of clinical isolates. 
Unlike CD46, which is ubiquitously expressed, SLAM expression is 
restricted to immune cells. This protein was originally identified on 
activated B and T lymphocytes (29, 170) but is expressed constitutively on 
immature thymocytes, memory T cells and certain B cells. Monocytes and 
dendritic cells express SLAM only following activation. Importantly, besides 
MV, other morbillivirus like canine distemper virus and rinderpest virus use 
SLAM (canine and bovine respectively) as their cellular receptor (187). 
Although murine immune cells express SLAM, which has 60% sequence 
identity to human SLAM and a similar function, it cannot act as MV 
receptor (126). 
In the next chapter we describe how we generated a mouse line 
expressing human SLAM with human-like tissue specificity and defective in 
the interferon response. In this chapter we present a detailed 
characterization of the expression profile of hSLAM in hSLAMGe transgenic 
mice and investigate the susceptibility of these mice to MV infection. We 
analyzed hSLAM expression in activated B and T cells, and in bone marrow 
derived macrophages. Human SLAM expression increases after activation 
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of these cell populations. Next we characterized the tissues supporting MV 
infection upon IN or IP inoculation.  
 
Materials and Methods 
Mouse strains. The establishment of a transgenic mouse line 
expressing hSLAM is described in Chapter 3. 
 
Mouse infections. All animal experimental procedures were 
performed according to protocols previously approved by the Mayo Clinic 
Institutional Animal Care and Use Committee. Five to 8-week-old animals 
were anesthetized with isoflurane (Novation, IL, USA) and infected IN with 
4x10
5
 tissue culture infectious dose 50% (TCID50) MV. Five to 8-week-old 
mice were infected IP with 8x10
6
 TCID50 for histological analysis or with 
1.5x10
6
 TCID50 for assessment of CAT activity in infected tissues. 
 
Generation of a wild type MV expressing the reporter gene 
chloramphenicol acetyltransferase. MVwtIC323 (here abbreviated wtMV) 
was obtained from an infectious cDNA derived from the Ichinoise B (IC-B) 
wild type strain and cloned in the plasmid p(+)MV323 (provided by Dr. K. 
Takeuchi, University of Tsukuba, Tsukuba, Japan) (182). wtMVCAT is a 
derivative of MVwtIC323 to which a transcription unit expressing the gene 
CAT was added downstream of the hemaglutinin (H) gene. Briefly, the CAT 
gene was obtained from the plasmid pcDNA3.1CAT. The restriction sites 
MluI and AatII were added to the CAT using the forward primer F 
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5’CGACGCGTATGGAGAAAAAAATCACTGG 3’ and reverse 5’ 
CGGACGTCTTTACGCCCCGCCCTG 3’ and amplified by a PCR reaction The 
CAT was then amplified using the pCR2.1 TOPO, and cloned using the 
restriction sites MluI and AatII in the expression plasmid pCG-vac-H. The 
segment H-CAT was then obtained from the resulting plasmid, pCG-vac2-H-
CAT, with the restriction sites PacI/SpeI and cloned in the plasmid p(+) 
MVvac (named MVvacCAT). The CAT was then obtained with the restriction 
sites PvuII/SpeI and cloned in the plasmid pCG-IC323-H. IC323-H-CAT was 
then cloned with PacI/SpeI in the full length p(+) MV323 coding for the wt 
genome. 
 
Rescue of viruses and preparation of virus stocks. Viruses were 
rescued as described by Radecke et al. (147). Briefly, the helper cell line 
293-3-46 stably expressing MV-N, MV-P and T7 polymerase was 
transfected by calcium phosphate precipitation using ProFection Kit 
(Promega, Madison, WI) with two plasmids, one containing the relevant 
MV genome and the other coding for the MV polymerase (pEMCLa). Three 
days after transfection, the helper cells were overlaid on Vero/hSLAM cells 
and the appearance of infectious centers was monitored. Single syncytia 
were picked and propagated on Vero/hSLAM cells. To prepare virus stocks, 
Vero/hSLAM cells were infected at a multiplicity of infection (M.O.I.) of 
0.03 and incubated at 37ºC. Cells were scraped in Opti-MEM 
(Gibco/Invitrogen Corp., Grand Island, NY) and viral particles were released 
by two freeze-thaw cycles. Titers were determined by TCID50 titration on 
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Vero/hSLAM cells according to the Spearman-Kärber method (86). A UV-
inactivated virus was prepared by incubating a vial containing 50 µl of 
wtMVCAT on a UVP CL-1000 UV crosslinker (UVP, Upland, CA) on ice. The 
virus was exposed to a UV light of 254 nm at 3 cm from a UV source of 1.85 
x10
5
 μJ/cm
2
 for 30 minutes. 
 
Isolation and activation of B and T lymphocytes. Spleen and 
thymus were collected aseptically and transferred into a 15 ml tube 
containing RPMI 1640 (Mediatech Inc., Herndon, VA) with 5% fetal bovine 
serum (FBS) (Gibco/Invitrogen Corp.) and 1% Penicillin/Streptomycin 
(Mediatech Inc.). To obtain single cell suspensions, spleen and thymus 
were transferred to a 70 µm cell strainer (BD Biosciences, Bedford, MA), 
smashed with the plunger of a syringe, washed with RPMI 1640 medium 
and resuspended in this medium.  
T and B cells isolated from the thymus and spleen respectively, 
were negatively separated by magnetically labeling cells with MACS 
microbeads (MiltenyiBiotec, Bergisch Gladbach, Germany) according with 
manufacturer’s recommendations. To activate the T lymphocytes, 96 well 
plates were coated over night at 4ºC with CD3 antibody (5 µg/ml) (BD 
Pharmingen). T lymphocytes were incubated for 24 hours at 37ºC in anti-
CD3 coated plates and interleukin-2 (IL-2) (100 U/ml). B cells were 
activated by incubating B lymphocytes with LPS (Sigma) (20 µg/ml) for 24 
hours at 37ºC.  
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Isolation and activation of macrophages. Femurs of 5-8 weeks 
Ifnar
ko
-SLAMGe and C57BL/6 mice were collected and cleaned with the 
help of a blade to remove adherent muscle tissue. Intact bones were then 
left in 70% ethanol for 5 minutes for disinfection and washed with 
phosphate buffered saline (PBS). Both ends were cut with scissors and the 
marrow flushed with PBS using a syringe with 0.45 mm diameter needle. 
Clusters within the marrow suspension were disintegrated by vigorous 
vortexing. After wash with PBS, about 1-1.5x10
7
 leukocytes were obtained 
per femur. 
At day 0 bone marrow (BM) leukocytes were seeded at 2x10
6
 per 
100 mm bacteriological petri dish in 10 ml complete medium (RPMI 1640 
(Mediatech Inc.) with 10% heat inactivated and filtered (0.22 µm, 
Millipore) FBS (Gibco/Invitrogen Corp.) and 1% Penicillin/Streptomycin 
(Mediatech Inc.). Cells were allowed to attach for 2 hours, after which the 
unattached were washed off with PBS. The attached cells were cultured 
with 10 ml of complete medium containing 200 U/ml of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and allowed to 
differentiate to macrophages for 3 to 5 days. Every third day medium was 
replaced with fresh medium containing GM-CSF. One day before 
harvesting, 500 U/ml of LPS (Sigma) was added to the culture medium. At 
day 5, medium was replaced by PBS/0.005% trypsin and the cells were 
gentle scraped and collected. Macrophages were analyzed for CD11b (also 
named Mac-1), F4/80, and hSLAM expression. C57Bl6 mice served as 
negative control. 
Results  Chapter 2 
 
49 
 
Flow cytometry. Different cell populations were identified with the 
following markers: for the identification of CD4
+
 T cells, anti-CD4-
fluorescein isothiocyanate (FITC) (GK1.5, BD Pharmingen) was used. For the 
identification of CD8
+
 T cells, cells were stained with anti-CD8-FITC 
(Lou/Ws1/M, BD Pharmingen). B lymphocytes were identified with anti-
CD45R (B220)-FITC (RA3-6B2, BD Pharmingen). Bone marrow derived 
macrophages were identified with the following stainings: anti-Mac-1-
PerCP (Peridinin chlorophyll protein) (M1/70, eBioscience) and anti-F4/80-
APC (BM8, eBioscience). 
SLAM expression was detected by incubating cells with PE anti-
human CD150 (A12, BD Pharmingen). Corresponding isotype antibodies 
were used as controls for antibody specificity. Acquisition of samples was 
performed on a cytometer (FacsCanto) and analyzed using FlowJo software 
(Tree Star, Inc., Asland, OR). 
 
Immunohistochemistry. Tissues were collected and prepared as 
described in Chapter 3. Briefly, frozen tissue sections 4-6 µm in thickness 
were incubated with anti-MV N polyclonal antibody (189), washed, 
counterstained and mounted.  
 
CAT assay. Animals were sacrificed and tissues removed and snap 
frozen in liquid nitrogen. Frozen tissues were grinded on ice in 500 µl of 
Tris-buffered saline (TBS), 1mM EDTA, and antiproteases (Calbiochem). 
After grinding, 500 µl of TBS, 1 mM EDTA and 1% Triton x100 were added 
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and the samples were subjected to vortex for 30 seconds and left on ice for 
30 minutes. The homogenates were then subjected to two freeze-thaw 
cycles and centrifuged at 12,000 rpm at 4ºC for 5 minutes. The supernatant 
was recovered and the protein concentration was measured by the 
Bradford method. For each tissue, 800 µg of protein in 500 µl volume was 
analyzed for CAT activity according to the supplier’s protocol (Molecular 
Probes). Briefly, 10 µl of FAST CAT (provided) substrate solution was added 
to the tissue extract and incubated at 37ºC for 5 minutes. The mixture was 
then incubated at 37ºC for 5 hours with 10 µl of acetyl coA (Sigma). The 
reaction was stopped by adding 1 ml of ice-cold ethyl acetate (Sigma) and 
the samples were vortexed for about 20 seconds. Samples were 
centrifuged at top speed for 3 minutes to separate the liquid phase. The 
top 900 µl of ethyl acetate were recovered and transferred to a clean 
Eppendorf tube and the solvent allowed evaporating. The residue was 
dissolved in 25 µl of ethyl acetate and stored in the dark at – 20ºC until 
further analysis. Samples were applied in a thin layer chromatography silica 
gel plate. The solvent was allowed to ascend the plate. Samples were air 
dried and the results visualized under UV-light. 
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Results 
Human SLAM expression in lymphocytes of hSLAM transgenic 
mice. To characterize the protein expression profile of hSLAM in the 
hSLAM transgenic mice, we purified B and T cells from the spleen and 
thymus, respectively, and analyzed hSLAM expression by flow cytometry. 
As SLAM expression in resting lymphocytes is expected to be very low (29), 
B cells were purified from the spleen and activated for 24 hours with LPS, 
stained with a B cell marker and analyzed for hSLAM expression. T cells 
were purified from the thymus and activated for 24 hours with CD3 
antibody and IL-2. 
Figure 1 documents hSLAM expression in one representative 
animal. The panels in Figures 1A, B and C document hSLAM expression 
levels in activated cells (red line) as compared to non activated cells (blue 
line) from Ifnar
ko
-SLAMGe mice and to non- activated cells from C57BL/6 
mice (green line). In non-activated B and CD4 and CD8 T cells hSLAM 
expression was very low whereas the expression levels increased after 
activation of B cells with LPS (Fig. 1A, red line) and CD4 and CD8T cells with 
anti-CD3 and IL-2 (Fig. 1B and C, red line). Thus, resting T and B cells from 
Ifnar
ko
-SLAMGe mice express human SLAM at low levels whereas 
expression increases following activation as previously described (29, 153, 
170).  
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Figure 1. Analysis of hSLAM expression in activated B and T lymphocytes 
from hSLAM transgenic mice. Activated (red lines) and non-activated (blue 
lines) B cells were stained with antibodies specific for B cells (B220) (A) and 
T cells (CD4) and (CD8) (B and C respectively) and SLAM. Activated cells of 
C57BL/6 mice served as negative controls (green lines). Histogram panels, Y 
axis: % of Max is a measure of the number of cells normalized to the same 
total number in each sample. 
 
 Human SLAM expression in macrophages of hSLAM transgenic 
mice. Since MV may infect initially macrophages or dendritic cells in the 
respiratory tract rather than epithelial cells (34) we characterized hSLAM 
expression in BM derived macrophages of Ifnar
ko
-SLAMGe mice. 
To generate macrophages, cells were harvested from the femurs of 
transgenic mice. Cells were allowed to attach and cultured with GM-CSF for 
3 to 5 days. Half of the cells were further cultured with LPS for activation. 
Bone marrow derived macrophages were analyzed for Mac-1, F4/80, and 
hSLAM expression.  
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Figures 2 documents hSLAM expression in activated cells (red line) 
as compared to non-activated cells (blue line) from Ifnar
ko
-SLAMGe mice 
and non-activated cells from C57BL/6 mice (green line).  
A small fraction of non-activated macrophages from Ifnar
ko
-SLAMGe 
mice expresses hSLAM compared with macrophages obtained from 
C57BL/6 mice (compare blue line with green line of C57BL/6 negative 
control), but a substantial increase in the percentage of cells expressing 
SLAM was documented following activation with LPS. 
 
 
Figure 2. Analysis of hSLAM expression 
in activated macrophages cultured 
from bone marrow of Ifnar
ko
-SLAMGe 
mice (red lines). Blue lines represent 
hSLAM expression in non activated 
macrophages. C57BL/6 mice were used 
as negative controls (green lines). 
 
 
 
  
  
 To assess whether macrophages from Ifnar
ko
-SLAMGe mice were 
susceptible to MV infection, cells obtained from BM of Ifnar
ko
-SLAMGe 
mice were activated and infected with wtMVgreen at an M.O.I. of 5 and 
analyzed by flow cytometry at 48 hours p.i.. 
As shown in Figure 3, inoculation of activated macrophages from 
Ifnar
ko
-SLAMGe mice resulted in receptor-dependent infection as 
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determined by GFP expression. Compare GFP expression in activated 
macrophages from Ifnar
ko
-SLAMGe mice (red line) with GFP expression in 
non-activated macrophages from Ifnar
ko
-SLAMGe or C57BL/6 mice (blue 
and green line respectively).   
 
Figure 3. Analysis of GFP expression in 
activated (red line) and in non activated 
(blue line) macrophages from Ifnar
ko
-
SLAMGe mice and C57BL/6 mice (green 
line). Cells were inoculated with 
wtMVgreen at an M.O.I. of 5 and analyzed 
by flow cytometry 48 hours later.  
 
 
 
 
Ifnar deficiency increases susceptibility to wild type MV 
replication in hSLAM transgenic mice. Previous studies with mice 
expressing hCD46 infected with the vaccine strain of MV, showed that Ifnar 
deficiency render mice more susceptible to MV infection (113). This effect 
was documented already 2-3 days post-infection. Therefore we bred SLAM 
transgenic mice into an Ifnar deficient background. As we plan to use our 
mice to characterize even earlier steps of MV infection we sought to 
determine whether interferon type I exerts its antiviral effect already one 
day after inoculation. Therefore, we inoculated Ifnar
ko
-SLAMGe and 
SLAMGe mice intraperitoneally with wtMV and analyzed MV infection. At 
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one day after inoculation, lymphatic organs (mediastinal LN and spleen) 
were harvested and analyzed by immunohistochemistry.  
Figure 4A and B shows a representative immunohistochemistry 
analysis of mediastinal LN one day after inoculation of SLAMGe (panel A) 
and Ifnar
ko
-SLAMGe mice (panel B). MV N protein was detected in this LN 
of Ifnar
ko
-SLAMGe mice, whereas no virus was detected in the 
corresponding LN of SLAMGe mice. In addition, Figure 4B shows that the 
virus is localized mainly in the subcapsular sinus of this LN and the 
presence of syncytial cells is documented (box in higher magnification on 
the low right corner of panel B). 
Figure 4C and D shows that MV replicated in the spleen of Ifnar
ko
-
SLAMGe mice (panel D, arrows), but not in the spleen of SLAMGe mice 
(panel C) one day p.i..  
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Figure 4. Identification of MV infection in the mediastinal LN and spleen 
of SLAMGe or Ifnar
ko
-SLAMGe mice one day after IP inoculation. Frozen 
sections of mouse mediastinal LN and spleen were stained with an anti-N 
antibody and counterstained with hematoxylin. N protein was visualized 
with red chromogen. 
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This suggests that interferon type I acts as an important restriction 
factor for MV replication in this animal model as early as 24 hours after 
infection.  
 
Spread of MV in Ifnar
ko
-SLAMGe mice. To be in the position of 
easily measure the levels of MV-based gene expression in different tissues, 
we generated a virus expressing the reporter gene CAT (Materials and 
Methods). A map of the plasmid constructed to generate the virus is shown 
in Figure 5. 
 
 
Figure 5. Map of the p(+) MV323 plasmid coding for the wt genome and 
location of the inserted CAT gene. Six coding regions of MV genes are 
represented by colored boxes. The T7 promoter, hepatitis delta virus 
ribozyme (HδR) and selected unique restriction sites are indicated. The CAT 
transcription unit was inserted between the PvuII and SpeI restriction sites 
downstream the H gene. 
 
Since the respiratory tract is the natural route of MV infection in 
humans, mice were inoculated intranasally with 4x10
5
 TCID50 of wtMVCAT. 
Lungs, thymus and spleen were harvested and CAT activity was assessed in 
the homogenates of these tissues (Fig. 6A). Inoculation with UV-inactivated 
virus served as negative control. No virus was detected in the homogenates 
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of tissues of mice infected with UV-inactivated virus (not shown). In 
contrast, viral replication was detected three days p.i. in the lungs of all 
animals inoculated with live virus and in the thymus of one of six animals. 
At day 6 virus was detected in spleen of one of six mice (Fig. 6A).  
We also tested an alternative route of inoculation and assessed 
viral spread after IP infection. Animals were inoculated with 1.5x10
6
 TCID50 
of wtMVCAT and viral replication was documented by the presence of CAT 
activity in the homogenates of lungs, thymus and spleen.  
As shown in Figure 6B, after IP infection MV replication was 
strongest in the spleen, it was detectable in the thymus of all mice at day 6 
but not at day 3, and it was detected also in the lungs at both 3 and 6 days 
p.i.. This pilot experiment suggests that these mice can serve as a model to 
study the initial steps of MV infection and pathogenesis.  
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Figure 6. MV spread in different organs of Ifnar
ko
-SLAMGe mice. Mice 
inoculated intranasally (A) or intraperitoneally (B) with wtMVCAT were 
sacrificed at days 3 or 6 p.i., tissues collected and homogenized and tested 
for CAT activity. As a positive control Vero/hSLAM cells infected with 
wtMVCAT were used (+CAT) and homogenates from organs of a non 
infected mice were used as a negative control (-CAT).  
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Discussion 
Since the identification of SLAM as the cellular receptor for wild 
type MV strains (44, 75, 186) several types of transgenic mice have been 
generated with the goal of serving as animals models for MV infection. 
These models differ in what concerns to the profile of hSLAM expression. 
Some of these animals cannot be used as a model for MV infection because 
SLAM expression is restricted to certain cell types (62, 63). In our 
transgenic mouse the use of a large fragment of the human genome 
including the locus control region resulted in a human-like expression 
profile. We documented hSLAM expression in activated B and T 
lymphocytes, and in macrophages following their activation. B and T cells 
were previously shown to be important targets for MV infection of SLAM 
‘’knock-in’’ mice: three days after IP infection up to 1% of B and T cells 
were infected by wild type MV (127).  
We also generated macrophages from Ifnar
ko
-SLAMGe transgenic 
mice and documented hSLAM expression following activation with LPS. 
SLAM expression was reported to be absent in resting monocytes (144, 
170). Nevertheless, it could be induced by mitogens and cytokines as well 
as with MV infection (109). Another finding was that macrophages 
expressing hSLAM were susceptible to MV infection in a receptor-
dependent manner. Consistent with the relevance of these cells as specific 
hosts for MV infection and dissemination is the fact that these cells are the 
major targets for a vaccine strain of MV in Ifnar
ko
-CD46Ge mice 
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independent of the route of infection (154). Thus, macrophages may play 
an important role in the initial phases of MV infection and dissemination.  
We also show that upon IN or IP infection MV replicates in the 
airways and in lymphatic tissues of Ifnar
ko
-SLAMGe mice. One interesting 
point is that two of six mice inoculated IP show some infection of the lungs 
three days post-inoculation. We do not know whether infection is due to 
infiltration of infected immune cells or direct infection of the respiratory 
epithelia.  
Based on these results we hypothesize that SLAM expressing 
macrophages or lymphocytes might constitute the major targets for MV 
infection upon respiratory inoculation and may be responsible for 
transmission of the virus to the lymphatic tissues. Following amplification 
of the virus in the lymphatic tissues infected immune cells may cross the 
airway epithelium and promote transmission to a new host. Thus, infection 
of these mice provide the ideal opportunity to characterize the early 
phases of MV infection and gain insights in the cell types supporting initial 
MV infection and dissemination.  
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CHAPTER 3 
Measles virus infection of alveolar macrophages and dendritic 
cells precedes spread to lymphatic organs in transgenic mice 
expressing human signaling lymphocytic activation molecule 
(SLAM, CD150) 
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Abstract 
Recent studies in primate models suggest that wild type measles 
virus (MV) infects immune cells located in the airways before spreading 
systemically, but the identity of these cells is unknown. To identify cells 
supporting primary MV infection we took advantage of mice expressing the 
MV receptor human signaling lymphocyte activation molecule (SLAM, 
CD150) with human-like tissue specificity. We infected these mice 
intranasally with a wild type MV expressing green fluorescent protein. One, 
two or three days after inoculation, nasal-associated lymphoid tissue, the 
lungs, several lymph nodes, spleen and thymus were collected and 
analyzed by microscopy and flow cytometry, and virus isolation was 
attempted. One day after inoculation MV replication was documented only 
in the airways, in about 2.5% of alveolar macrophages and 0.5% of 
dendritic cells. These cells expressed human SLAM, and it was observed 
that MV infection temporarily enhanced SLAM expression. Later, MV 
infected other immune cell types including B and T lymphocytes. Virus was 
isolated from lymphatic tissue as early as two days post IN inoculation; the 
mediastinal lymph node (LN) was an early site of replication, and supported 
high levels of infection. Three days after intraperitoneal inoculation 1-8% of 
the mediastinal LN cells were infected. Thus, MV infection of alveolar 
macrophages and sub-epithelial dendritic cells in the airways precedes 
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infection of lymphocytes in lymphatic organs of mice expressing human 
SLAM with human-like tissue specificity. 
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Introduction 
Measles virus, a member of the Morbillivirus genus of the 
Paramyxoviridae family, causes measles, a highly contagious disease 
transmitted by respiratory aerosols that induces a transient but severe 
immunosuppression (59, 161). In spite of eradication efforts, MV still 
accounts for about 4% of deaths in children aged under five years 
worldwide (16, 110), mainly due to opportunistic secondary infections 
facilitated by MV-induced immune suppression (59). Experimental analyses 
of the mechanisms of pathogenesis, including the characterization of cells 
and tissues supporting primary MV infection, is limited by host species 
specificity: old world monkeys and humans are the only natural MV hosts.  
MV replication has been characterized mainly around the time of 
rash appearance, 10-14 days after experimental infection of monkeys (33, 
34, 108, 185). Viremia in blood cells peaks at or slightly before rash: 
infected B and T lymphocytes, monocytes and dendritic cells (DC) are 
detected, while little if any cell-free virus is produced. Infected cells express 
the signaling lymphocytic activation molecule (SLAM, CD150), the 
lymphatic cell MV receptor (44, 75, 186). More information about the 
cellular targets of wild type MV infection in the airways immediately after 
contagion is important: recent studies in monkeys have suggested that MV 
may replicate initially in immune cells in the airways (34, 99) rather than in 
lung epithelial cells as previously postulated (31, 157). 
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 Limited availability and high costs of primate experimentation 
motivated the development of transgenic rodent models of MV infection. 
Studies in the ‘90s were based on mice expressing human membrane 
cofactor protein (MCP, CD46), the receptor used only by the attenuated 
MV strain (39, 119, 204). These studies indicated that airway macrophages 
are infected by the MV vaccine strain in the first days after intranasal (IN) 
inoculation, and that blood monocytes and tissue macrophages 
disseminate the infection (113, 154). To increase susceptibility to MV 
infection, CD46-expressing mice were crossed into an interferon receptor 
knock-out (Ifnar
ko
) background; this did not appear to change the cell type 
specificity of viral replication (154). 
 After human SLAM (hSLAM) was characterized as the immune cell 
receptor for wild type and vaccine MV, several mouse strains expressing 
this protein were generated, as recently reviewed (164). SLAM is a 70-kDa, 
type I transmembrane glycoprotein expressed on immune cells such as 
activated T cells, B cells, monocytes/macrophages, and DC (29). It belongs 
to the immunoglobulin protein superfamily and has two extracellular 
domains named V and C2; V interacts with the MV attachment protein 
hemagglutinin (133). SLAM determines Th2 cytokine production such as IL-
4 and it may be involved in the production of IL-12, TNF-α, and nitric oxide 
by macrophages (171, 192, 200). In addition, SLAM may induce B cell 
proliferation and immunoglobulin synthesis. Importantly, hSLAM-
expressing mice but not CD46-expressing mice can be infected by wild type 
MV strains that use SLAM but not CD46 as receptor (120). 
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 Initially a model expressing hSLAM under control of the T-cell 
specific lck promoter was reported (62). In this model hSLAM expression 
was restricted to immature and mature lymphocytes in the spleen, thymus, 
and blood; lymphocyte proliferation was observed, but there were no 
clinical signs of disease. The second model was a mouse in which the 
hSLAM coding sequence was expressed under control of the promoter of 
the ubiquitously expressed HMGCoA protein (163). In suckling mice 
generalized but not necessarily relevant infections of most of the major 
organs were documented. Adult mice were less susceptible to MV 
infection: only intracerebral inoculation was productive, and yielded viral 
proteins but no infectious virus. The third model consisted of a transgenic 
mouse expressing hSLAM in DC from a cDNA under control of the CD11c 
promoter (63). MV infections are limited to DC in this model and disrupt 
the function of these cells in stimulating adaptive immunity.  
 An alternative approach to transgenesis seeks human-like tissue 
specificity of expression. Towards this, Shingai et al. (168) added a full-
length hSLAM gene to the mouse genome, showed that indeed these mice 
express hSLAM with human-like tissue specificity, and crossed them in an 
Ifnar
ko
 and human CD46-positive background. In this model CD11c-positive 
DC are instrumental to establish MV infections. The fifth mouse strain was 
generated by exchanging only the MV binding site on mouse SLAM with 
that in the V domain of hSLAM (127). Since human and mice have similar 
tissue specificity of SLAM expression, this led to human like expression. 
When these mice were crossed in an Ifnar
ko
 background, efficient MV 
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replication suppressing proliferative responses to concanavalin A was 
documented. 
We previously generated a mouse strain expressing hSLAM with 
human-like tissue specificity in a STAT1-deficient background (202) We 
showed that hSLAM expression was restricted to B and T lymphocytes and 
some monocytes/macrophages, and that it was inducible by LPS, lectins or 
anti-CD3 antibodies in immune cells, as in primates. Since the Ifnar
ko
 
background allows more efficient MV spread (113, 154) without apparent 
effects on the cell type specificity of MV infection in mice (127, 168), we 
crossed here these mice in the Ifnar
ko
 background. We then used the 
Ifnar
ko
-SLAMGe mice to identify the cells infected by wild type MV 
immediately after IN inoculation. We document efficient early infection of 
alveolar macrophages (AM) and DC. We also observed subsequent 
infection of all lymphatic organs, and in particular of the mediastinal LN, 
upon both IN and intraperitoneal (IP) inoculation.  
 
Materials and Methods 
Mouse strains. To establish a transgenic mouse line expressing the 
hSLAM gene and deficient in the alpha/beta interferon response, Ifnar
ko
-
CD46Ge mice (113) were crossed with SLAMGe mice (202). The hSLAM 
gene was added to the genome of congenic C57Bl/6 mice (202), but the 
Ifnar
ko
-CD46Ge mice is on a mixed C57Bl/6 and C3H background (113), and 
the crossing yields a mixed background. To obtain homozygous Ifnar
ko
-
SLAMGe mice, the F2 and F3 progeny was screened for inactivation of both 
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copies of the interferon alpha receptor gene (114) for availability of two 
copies of the hSLAM gene, and for absence of the CD46 gene.  
Since no simple PCR test for the hSLAM genotype was available, the 
site of insertion of the hSLAM gene in the mouse genome was 
characterized. To accomplish this, primers specific for terminal sequences 
of the human genome inserted in the bacterial artificial chromosome used 
for transgenesis (202) were synthesized. These primers were used in 
combination with primers provided in the GenomeWalker Universal Kit (BD 
Pharmingen, San Diego, CA) to identify the insertion site of hSLAM in the 
mouse genome, after nucleotide 47,072,810 of chromosome 12, in band 
B3 (mouse genome sequence available through www.ensembl.org). The 
hSLAM specific analysis was then based on two combined PCR reactions. 
SLAM PCR 1 used the primers pairs: 5’– 
GTGTCACCTAAATAGCTTGGCGTAATCATG and 5’– 
GTTAATATAGACAATGCCCATCTCCAGCAG, amplifying a 1030 base pair band 
including part of the hSLAM gene and part of the mouse chromosome 12. 
SLAM PCR 2 used the primer pairs 5’- 
AGCTTTCTGAATAGGGGTGTTACTTAATGC and 5’- 
GTTAATATAGACAATGCCCATCTCCAGCAG, amplifying a 1339 base pair band 
of mouse chromosome 12. Mice homozygous for the hSLAM gene had a 
positive signal from PCR 1 and no signal from PCR 2. 
 
Mouse infections. All animal experimental procedures were 
performed according to protocols previously approved by the Mayo Clinic 
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Institutional Animal Care and Use Committee. Five to 8-week-old animals 
were anesthetized with isoflurane (Novation, IL, USA) and infected IN with 
8x10
5
 tissue culture infectious dose 50% (TCID50) MV in 100 μl divided in 
two doses of 50 μl (25μl in each nare) in Opti-MEM. Ten minutes elapsed 
between both inoculations. Five to 8-week-old mice were infected IP with 
1.5x10
6
 TCID50 in 1 ml Opti-MEM to measure viral load in lymphatic tissues; 
for the experiments of Table 3 the TCID50 was 8x10
6
. IN and IP infections 
with ten-fold smaller inocula were productive, but the results were difficult 
to quantify. 
 
Viruses and virus stock preparation. MVwtIC323 (here abbreviated 
wtMV) was obtained from an infectious cDNA derived from the Ichinoise B 
(IC-B) wild type strain and cloned in the plasmid p(+)MV323 (provided by 
Dr. K. Takeuchi, University of Tsukuba, Tsukuba, Japan) (182). wtMVgreen is a 
derivative of MVwtIC323 to which a transcription unit containing the open 
reading frame of enhanced green fluorescence protein (GFP) (40) was 
added upstream of the nucleocapsid gene (99). Viruses were amplified on 
Vero/hSLAM cells as described by Radecke et al. (147). Cells were scraped 
in Opti-MEM (Gibco/Invitrogen Corp., Grand Island, NY) and viral particles 
were released by two freeze-thaw cycles. Titers were determined by TCID50 
titration on Vero/hSLAM cells according to the Spearman-Kärber method 
(86). 
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Blood and organ collection, and preparation of single cell 
suspensions. Blood samples obtained by cardiac puncture at terminal 
bleeding were collected in a microtainer tube with lithium heparin (Becton 
Dickinson, Franklin Lakes, NJ). Peripheral blood mononuclear cells (PBMCs) 
were isolated by density gradient centrifugation with Ficoll-Paque Plus (GE 
Healthcare, Sweden).  
Nasal associated lymphoid tissue (NALT), LN, spleen and lungs were 
collected aseptically and transferred into a 15 ml tube containing RPMI 
1640 (Mediatech Inc., Herndon, VA) with 5% fetal bovine serum (FBS) 
(Gibco/Invitrogen Corp.) and 1% Penicillin/Streptomycin (Mediatech Inc.). 
NALT was collected as follows (5): the facial skin was stripped from the 
head and the nose tip was cut off including the front teeth. The cheek 
muscles and cheek bones were taken off. The soft and the hard palate 
were removed and the NALT was excised distal to the emergence of the 
palatine nerve. To obtain single cell suspensions, NALT, LN and spleen were 
transferred to a 70 µm cell strainer (BD Biosciences, Bedford, MA), mashed 
with the plunger of a syringe, washed with RPMI 1640 medium and 
resuspended in this medium.  
Single cell suspensions from lungs were generated as described in 
(158) with some modifications. Briefly, the lungs were aseptically collected 
in 10 ml of RPMI 1640 with 5% FBS and 1% Penicillin/Streptomycin, 
reduced to small pieces (approximately 1-2 mm
2
) and digested at 37 ºC for 
1 hour in 10 ml phosphate buffered saline (PBS) (Mediatech) containing 
300 U/ml collagenase type II (Worthington, Lakewood, NJ) and 0.15 mg/ml 
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DNase (Roche Diagnostics, Germany). After digestion, lung pieces were 
minced with the plunger of a syringe and washed in a 70 µm pore size cell 
strainer with RPMI 1640. Cells were centrifuged and resuspended in 3 ml of 
red cell lysis buffer (ACK lysis buffer, 0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM 
EDTA, pH 7.2) and incubated at 37 ºC for 3 minutes. Cell suspensions were 
washed once with RPMI 1640 medium in a 70 µm pore size cell strainer, 
centrifuged and resuspended in RPMI 1640 medium. 
 
Immunohistochemistry and immunofluorescence. Initial 
preparation of tissues was as follows: tissues were collected at different 
time points after infection, embedded in Tissue Tek OCT compound (Sakura 
Finetek, Torrence, CA) and frozen by immersion in liquid nitrogen-cooled 
methylbutane (Sigma-Aldrich Inc., St.Louis, MO). Tissue sections 4-6 µm in 
thickness were obtained, fixed in 99.5% histological grade acetone (Sigma-
Aldrich) and stored at -80ºC until further use. Sections were thawed at 
room temperature (RT) for 5 minutes and fixed in 2% paraformaldehyde 
solution (USB Corporation, Cleveland, OH) for 10 minutes. 
For immunohistochemistry staining, frozen sections were incubated 
with peroxidase blocking reagent (Dako, Carpinteria, CA) for 30 minutes at 
RT, followed by incubation with background reducer solution (Background 
Sniper, Biocare Medical, Concord, CA) for 30 minutes at RT, and by 
incubation with anti-MV N polyclonal antibody (189) diluted in Background 
Sniper solution for 1 hour at RT. Sections were then washed with Bio-Rad 
Tris-buffered saline [20 mM tris (hydroxymethyl) aminomethane, 500 mM 
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NaCl] and incubated with rabbit or rodent alkaline phosphatase-polymer 
solution (Biocare Medical) for 20 minutes at RT. Alkaline phosphatase was 
visualized with red chromogen substrate (Biocare Medical). Sections were 
counterstained with hematoxylin (Vector, Burlingame, CA) and mounted 
with permanent mounting medium (Vector).  
For immunofluorescence stainings, sections were permeabilized for 
3 minutes at RT in PBS with 0.1% (v/v) Triton X-100 (Sigma-Aldrich). 
Sections were incubated with 5% goat serum blocking solution for 30 
minutes at RT. Streptavidine-biotin blocking was performed prior to 
incubation of sections with biotinylated anti-MHC class II (I-A
b
) antibody, 
using a streptavidin-biotin blocking kit (Vector). After blocking, sections 
were incubated one hour at RT with antibodies diluted according to 
manufacturer’s recommendations in blocking solution. MV N protein was 
detected with a rabbit polyclonal anti-MV N antibody (described above) at 
a dilution of 1/100 followed by incubation with Alexa Fluor 488-conjugated 
anti-rabbit IgG (Invitrogen, Molecular Probes, Eugene, OR). B lymphocytes 
were identified with anti-CD45 (B220) (clone RA3-6B2; BD Biosciences 
Pharmingen); CD4 and CD8 T cells were identified with anti-CD4 (YTS191.2; 
Abcam Inc., Cambridge, MA) and anti-CD8 (YTS169.4; Abcam) respectively; 
AMs were characterized with anti-CD2 (LFA-2) (RM2-5, eBioscience, San 
Diego, CA); anti-CD11c (223H7; MBL International, Woburn, MA); anti-
F4/80 (Cl:A3-1, Abcam); biotinylated mouse monoclonal anti-MHC class II 
(I-A
b
) (AF6-120.1, BD Pharmingen) and anti-Mac-1 (M1/70, eBioscience). 
Epithelial cells were identified with anti-CD326 (Ep-CAM, Epithelial Cell 
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Adhesion Molecule) (G8.8, BD Biosciences Pharmingen). Secondary 
antibodies included Alexa Fluor 594-conjugated anti-rat IgG (Invitrogen). 
Sections stained with biotinylated mouse monoclonal anti-MHC class II (I-
A
b
) as primary antibody were stained with Alexa 594 conjugated-
streptavidin (Invitrogen) as the secondary antibody. Sections were 
mounted in Prolong Gold antifade reagent with DAPI (Invitrogen, Molecular 
Probes) and visualized with a Zeiss Axioplan confocal microscope (LSM 510; 
Carl Zeiss Inc., Germany). 
 
Flow cytometry. For flow cytometry analysis, whole lungs were 
collected without lavage, to allow the inclusion of bronchoalveolar cells. A 
single cell suspension was prepared as described above. Cells were counted 
using a hemacytometer after diluting with trypan blue dye to exclude dead 
cells. Isolated cells were resuspended at a density of 10
6 
cells/50 µl. To 
identify specific cell sub-populations a multicolor staining was performed 
by incubating cells with appropriate antibodies (1 µg per million cells), for 
45 minutes on ice. GFP was assessed to identify MV infected cells. For the 
identification of CD4
+
 T cells, anti-CD4-phycoerythrin (PE) (H129.19, BD 
Pharmingen) and anti-CD3-allophycocyanin (APC)-Cy7 (17A2, eBioscience) 
antibodies were used. For the identification of CD8
+
 T cells, cells were 
stained with anti-CD8-PE-Cy7 (53-6.7, eBioscience) and anti-CD3-APC-Cy7 
(eBioscience) antibodies. B lymphocytes were identified with anti-CD45R 
(B220)-APC-Cy7 (RA3-6B2, eBioscience). In order to reduce Fc receptor 
binding, cells stained with CD45R (B220) antibody (B cells) were first 
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incubated with CD16/32 antibody (2.4G2, BD Pharmingen) for 5 minutes on 
ice. DC (conventional dendritic cells) were identified with anti-MHCII (I-A
b
)-
PE (AF6-120.1, BD Pharmingen) and anti-CD11c-APC (HL3, BD Pharmingen). 
Macrophages were stained with anti-CD11c-APC (HL3, BD Pharmingen) and 
anti-Mac-1-PE-Cy5 (M1/70, eBioscience). AM were identified with the 
following staining: anti-Mac-1-PE-Cy5 (M1/70, eBioscience), anti-F4/80-
APC-Cy7 (BM8, eBioscience), anti-CD11c-APC (HL3, BD Pharmingen) and 
anti-MHCII (I-A
b
)-PE (AF6-120.1, BD Pharmingen). Epithelial cells were 
identified with anti-CD326-PE (Ep-CAM) (G8.8, BD Pharmingen). Ifnar
ko
-
CD46Ge mice were used as negative controls for quantification. 
Human SLAM expression was detected by incubating cells with 
biotin anti-human CD150 (A12 (7D4), BioLegend, San Diego, CA) followed 
by incubation with streptavidin-PerCP (Becton Dickinson 
Immunocytometry Systems, San Jose, CA). Ifnar
ko
-CD46Ge mice were used 
as negative controls and mock-infected animals were used as a negative 
control for GFP expression. Acquisition of samples was performed on a 
cytometer (FacsCanto or LSRII, BD Biosciences) and analyzed using using 
FlowJo software (Tree Star Inc., Asland, OR). Statistical analysis was 
performed with standard paired t tests using the JMP7 software (SAS, Cary, 
NC). 
 
Quantification of virus load in lymphatic organs. Single cell 
suspensions from mandibular, mediastinal, mesenteric and inguinal LN and 
spleen were obtained as described above. Serial 10-fold dilutions of 
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mononuclear cells were made in DMEM with 5% FBS and 1% 
Penicillin/Streptomycin. Four replicates of 10
1
 to 10
5
 mononuclear cells 
were co-cultured with 5x10
5
 Vero/hSLAM cells in 24-well plates and 10
6
 
mononuclear cells were co-cultured with 10
6
 Vero/hSLAM cells in a 100 
mm dish. Cultures were monitored for cytopathic effects 4 days later. Virus 
titers were expressed as TCID50 per 10
6
 cells. 
 
Results 
 Ifnar
ko
-SLAMGe transgenic mice.  To generate mice susceptible to 
wild type MV infection, the hSLAM gene, including all its transcription 
control elements, was previously transferred to the mouse genome (202). 
In another approach to enhance replication of any exogenous virus in mice 
(114), the mouse interferon type I receptor gene was inactivated (Ifnar
ko
 
background). For our study we combined these desirable characteristics by 
crossing hSLAM-expressing with Ifnar
ko
 mice; to facilitate progeny 
screening, we mapped the insertion site of the hSLAM gene in the mouse 
genome, as detailed in the materials and methods. The resulting mouse 
strain was named Ifnar
ko
-SLAMGe. It is defective in the interferon type I 
response and expresses hSLAM with human-like tissue specificity: for 
example, 11-13% CD3 positive T cells of these mice express hSLAM (data 
not shown), as compared to 10-20% CD3 positive T cells of humans (29, 
170); 28-31% CD19 positive B cells of these mice express hSLAM, as 
compared to 20-25% CD20 positive B cells of humans (data not shown). 
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 Human SLAM expression in lymphatic tissue of Ifnar
ko
-SLAMGe 
transgenic mice. We document here cell type specificity of  hSLAM 
expression in the mediastinal LN, previously shown to be important for MV 
infection of SLAM “knock-in” mice (127): in these mice MV reaches higher 
titers in this LN than in other lymphatic organs. Single cell suspensions 
were prepared from the mediastinal LN of five uninfected Ifnar
ko
-SLAMGe 
mice and stained with specific markers to indentify B cells (B220), T cells 
(CD3), and macrophages (CD11c
low
Mac-1
high
). Cells were gated for live 
leukocytes and analyzed for hSLAM expression within each cell population.  
 Figure 1 documents hSLAM expression in one representative 
animal: about 5% B cells (Fig. 1A, left panel, compare top left and right 
quadrants) and 2% T cells (Fig. 1B, left panel, compare top left and right 
quadrants) scored positive; the right panels in Figures 1A and 1B document 
hSLAM expression levels in Ifnar
ko
-SLAMGe mice (red line) as compared to 
a negative control (Ifnar
ko
-CD46Ge mice, blue line). The mean and standard 
deviation of SLAM expression in mediastinal LN of five animals were 10 ± 
5.9% for B cells and 1.5 ± 0.6% for T cells (data not shown). Thus resting B 
and T cells from mediastinal LN of Ifnar
ko
-SLAMGe mice express hSLAM at 
low levels, and more B than T cells express this protein, as in human 
lymphatic tissues (7, 30). In CD11c
low
Mac-1
high 
macrophages of this mouse 
(Fig. 1C, left panel, bottom right quadrant) hSLAM expression was below 
detection level (Fig. 1C, right panel). 
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Figure 1. Analysis of 
hSLAM expression in 
leukocytes from the 
mediastinal LN of Ifnar
ko
-
SLAMGe mice. Cells were 
stained with antibodies 
specific for B cells (B220
+
) 
(A), T cells (CD3
+
) (B) or 
macrophages 
(CD11c
low
Mac-1
high
) (C). 
Ifnar
ko
-CD46Ge mice were 
used as negative controls 
(right panels, blue lines). 
Right panels, Y axis: % of 
Max is a measure of the 
number of cells normalized 
to the same total number 
in each sample. 
 
 
 
 
Human SLAM expression in immune cells of the lungs of Ifnar
ko
-
SLAMGe transgenic mice. Since primary wtMV replication occurs mainly if 
not exclusively in immune cells, rather than in epithelial cells (99), SLAM-
expressing immune cells in the airways or in sub-epithelial tissue are 
candidate hosts for virus replication. We thus characterized hSLAM 
expression in single cell suspensions obtained from lungs of uninfected 
Ifnar
ko
-SLAMGe mice, including B cells (B220
+
), T cells (CD3
+
) and alveolar 
Results  Chapter 3 
 
81 
 
macrophages (AM) defined as CD11c
high
MHCII
low
Mac-1
low
F4/80
high
 cells (53, 
93). 
 
 
 
Figure 2. Analysis of SLAM 
expression in leukocytes from 
the lungs of Ifnar
ko
-SLAMGe 
mice. For (A) and (B), 
lymphocytes were gated and 
sorted with antibodies against 
B cells (B220
+
) or T cells 
(CD3
+
), respectively. For AM 
(C), total live cells were 
stained with three antibodies 
and sorted for the 
combination 
CD11c
high
MHCII
low
Mac-1
low
. 
Ifnar
ko
-CD46Ge mice were 
used as negative controls. 
Histogram panels, Y axis: % of 
Max is a measure of the 
number of cells normalized to 
the same total number in each 
sample. (C) y axis: FSC, 
forward scatter. 
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Figure 2 documents hSLAM expression in these cells: about 5% of B 
cells (Fig. 2A, left panel, compare top left and right quadrants) and 4% of T 
cells (Fig. 2B, left panel, compare top left and right quadrants) of one 
animal scored positive; the right panels in Figures 2A and 2B document 
hSLAM expression levels in Ifnar
ko
-SLAMGe mice (red line) as compared to 
a negative control (Ifnar
ko
-CD46Ge mice, blue line). The mean and standard 
deviation of SLAM expression in lung tissue of five animals were 8.7 ± 1.9% 
for B cells and 3.3 ± 0.7% for T cells (data not shown). A small fraction of 
AM also express SLAM (Fig. 2C, lower left panel, compare red line of 
Ifnar
ko
-SLAMGe mice with blue line of Ifnar
ko
-CD46Ge negative control 
mice).  
 
  Early MV replication in the lungs of Ifnar
ko
-SLAMGe transgenic 
mice. We then sought to identify the tissue and cell types sustaining wtMV 
replication immediately after IN inoculation of Ifnar
ko
-SLAMGe mice. 
Candidate host tissues/cell types include NALT and immune cells in the 
airway lumen or sub-epithelial airway tissue. Mice were inoculated with 
wtMVgreen, a GFP-expressing virus; since wtMV interacts with SLAM but not 
CD46, Ifnar
ko
 mice expressing CD46 but not SLAM served as negative 
control. One to seven days after IN inoculation, as indicated in Table 1, 
NALT and the lungs were harvested; in addition, mandibular and 
mediastinal LN, thymus, spleen and PBMC were collected. Cells from these 
organs were co-cultured with Vero/hSLAM cells and the appearance of 
syncytia was monitored over 4 days.  
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As shown in Table 1 MV was isolated from the lungs of every 
Ifnar
ko
-SLAMGe mouse at every time point. Virus was also isolated from the 
lungs of all three Ifnar
ko
-CD46Ge mice sacrificed 1 day p.i., but not at later 
time points (data not shown) suggesting that some of the virus re-isolated 
at day 1 may be the inoculum. At 2 days p.i., virus was recovered from the 
mediastinal LN in 2 out of 3 animals. At 3 and 7 days p.i., virus was isolated 
from the mediastinal LN and the spleen of most mice, and from the 
mandibular LN, thymus and PBMC of some mice. However, no virus was 
isolated from the NALT of any animal. These observations suggest that MV 
replicates initially in the lungs of Ifnar
ko
-SLAMGe mice, and then spreads to 
lymphatic organs through infected cells circulating in the lymphatics rather 
than in the blood.  
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TABLE 1. MV re-isolation from organs of Ifnar
ko
-SLAMGe mice after IN 
infection 
Organs Nº. positive/total nº. 
 Day 1
a
 Day 2 Day 3 Day 7 
Lungs 5/5 3/3 3/3 3/3 
NALT 0/5 0/3 0/3 0/3 
Mandibular LN 0/5 0/3 1/3 2/3 
Mediastinal LN 0/5 2/3 3/3 3/3 
Thymus 0/5 ND
b
 0/3 2/3 
Spleen 0/5 0/3 3/3 2/3 
PBMC 0/5 0/3 1/3 1/3 
a
 day post-infection. 
b 
ND, not done. 
 
To assess whether the inoculum accounts for a significant fraction 
of the signal detected after inoculation, we infected Ifnar
ko
-SLAMGe mice 
IN with UV-inactivated MVgreen. Mice were sacrificed one, two or three days 
after inoculation and whole lungs examined under a fluorescence 
microscope; no fluorescence was detected in mice infected with UV-
inactivated virus. On the other hand, the pattern of GFP expression was 
quite homogeneous; in four of four Ifnar
ko
-SLAMGe mice inoculated with 
live virus green fluorescence was observed in all the lobes of the lung, and 
reached into the lower respiratory airways (data not shown). As an 
additional control, we infected Ifnar
ko
-CD46Ge mice with MVgreen but again 
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no fluorescence was detected in the lungs of these animals (data not 
shown). Since the UV-inactivated inoculum is not detectable by analysis of 
GFP fluorescence, we conclude that one day post-inoculation significant 
MV replication accounts for strong GFP expression. 
 
AM sustain MV replication in the lungs. We then assessed by 
immunohistochemistry (Fig. 3A and B) and immunofluorescence (Fig. 3C to 
H) which cell types sustain MV replication in the airways. Ifnar
ko
-SLAMGe 
mice were infected IN with wtMVgreen, lungs collected one day post-
inoculation, frozen, and stained with an anti-N antibody (red colour). Figure 
3, panels A and B, shows one representative immunohistochemistry 
analysis: MV N protein was most often detected in cells located on the 
luminal side of respiratory bronchioles, a location typical for AM.  
To assess the identity of infected cells and differentiate between 
AM and other immune cells including DCs, we stained lung sections with an 
anti-N antibody (green colour) and different cellular markers: the immune 
cells markers CD11c, F4/80, CD2 (also named LFA-2), Mac-1 (also named 
CD11b) and MHCII, and the epithelial cell marker EpCAM (53, 93). None of 
the infected cells were EpCAM positive (Fig. 3G), suggesting that epithelial 
cells are not infected. Infected cells were often CD11c, F4/80, and CD2 
positive (Fig. 3 C-E), but very rarely Mac-1 or MHCII positive (Fig. 3F and 
Fig. 3H). Even if none of the above markers is entirely specific for one type 
of immune cells, altogether these results suggest that AM may sustain 
primary MV infection in the lungs.  
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Figure 3. Characterization of wtMV-infected cells in the lungs one day 
after mouse inoculation. (A and B) Frozen sections of mouse lung stained 
with an anti-N antibody and counterstained with hematoxylin. N protein 
was visualized with red chromogen. Arrows indicate positive cells, which 
localize in the airway lumen. (C to H) Identification of the cell types 
accumulating MV N by confocal micrographs analysis of lung frozen 
sections. N protein was visualized with Alexa Fluor 488 (green). The specific 
cell markers indicated on the top right of each panel were visualized with 
Alexa Fluor 594 (red). Nuclei were conterstained in blue with DAPI. Scale 
bars represent 10 µm. 
 
To quantify the level of infection of AM and other immune cell 
types mice inoculated IN with wtMVgreen were sacrificed 1 or 3 days later. 
Lungs were collected, tissue cells were dissociated, and GFP expression 
analyzed using flow cytometry. The analysis presented in Table 2 indicates 
that AM (sorted as CD11c
high
MHCII
low
Mac-1
low
F4/80
high
 cells) were infected 
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at the highest levels (2.4 ± 0.9%) one day post-inoculation (P = 0.0016 
between AM and epithelial cells). Conventional DC (sorted as 
MHCII
high
CD11c
high
 cells) were infected at about five times lower levels (0.5 
± 0.2%; P = 0.0024 between DC and epithelial cells), whereas only 0.1-0.3% 
of different populations of lymphocytes were infected. Near background 
(0.1%) levels of infection of epithelial cells was documented.  
 
TABLE 2. Percentile of MV-infected cells in the lungs 1 and 3 days after IN 
inoculation
 b 
 
          Cell type
 a
 Day 1 (6 mice) Day 3 (10 mice) Mock (5 mice) 
B cells (B220
+
)
 a
 0.3 ± 0.1 (8-64)
 b
 0.1 ± 0.1 (1-20) 0 
CD4
+
 T cells (CD3
+
CD4
+
) 0.2 ± 0.1 (1-7) 0.7 ± 0.8 (0-52) 0.01 ± 0.02 (0-1) 
CD8
+
 T cells (CD3
+
CD8
+
) 0.1 ± 0.04 (1-3) 0.1 ± 0.1(0-3) 0 
DC (MHCII
high
CD11c
high
) 0.5 ± 0.2 (5-11) 0.3 ± 0.2 (0-4) 0.1 ± 0.2 (0-2) 
AM (CD11c
high
MHCII
low 
Mac-1
low
F4/80
high
)
 
Monocytes (Mac-1
high
CD11c
low
) 
2.4 ± 0.9 (90-330) 
 
0 
0.7 ± 0.4 (9-77) 
 
0.4 ± 0.2 (2-10) 
0 
 
0 
Epithelial cells (EpCAM
+
) 0.1 ± 0.02 (4-13) 0.1 ± 0.1 (1-10) 0.04 ± 0.02 (2-4) 
a
 number of cells counted were over 5,000 B cells, AM and epithelial cells; 
about 3,000 CD4
+
 and CD8
+
 T cells, about 1,500 monocytes, and about 
1,200 DC  
b
 average ± standard deviation (range of counts) 
 
At day 3 post-infection low (0.1-0.7%) levels of infections were 
documented in all immune cell types analysed, with AM and CD4 T cells 
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being infected at the highest levels; monocytes that are available in 
unperfused lungs were infected at similar levels as other immune cell types 
(0.4%). Epithelial cell infection remained near background (0.1%). These 
data confirm that AM are the main initial target cells for MV infection, and 
also indicate that MV replication in immune cells located in the mouse 
airways is limited and short-lived. We also detected cellular infiltrates in 
the lungs 3 days p.i., which was due mainly to neutrophils (data not 
shown). 
 
MV infects AM expressing SLAM, and MV infection enhances 
SLAM expression. To assess whether hSLAM expression correlates with MV 
infection, we inoculated Ifnar
ko
-SLAMGe mice IN with MVgreen and analyzed 
hSLAM expression on AM collected one day after inoculation. AM from 
mock-infected Ifnar
ko
-SLAMGe mice, and from infected Ifnar
ko
-CD46Ge 
mice, served as controls. AM were sorted as CD11c
high
 (Fig. 4, left panels), 
MHCII
low
 (Fig. 4, center-left panels), Mac-1
low
 (Fig. 4, center-right panels) 
cells.  
Figure 4A (right panel, right quadrants) shows that background 
(0.12%) SLAM expression was detected in AM from control Ifnar
ko
-CD46Ge 
mice. On the other hand, 0.86% AMs of Ifnar
ko
-SLAMGe mice mock-
infected with the post-nuclear fraction of uninfected Vero/hSLAM cells 
expressed SLAM (Fig. 4B, right panel, right quadrants). Remarkably, about 
16% (1.44% GFP-positive and 14.8% GFP-negative) AMs of infected Ifnar
ko
-
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SLAMGe mice expressed SLAM (Fig. 4C, right panel), which may reflect AM 
activation.   
  
 
 
D 
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Figure 4. Analysis of hSLAM expression in AM before and after MV 
infection. AM from non-infected Ifnar
ko
-CD46Ge mice (A), mock-infected 
Ifnar
ko
-SLAMGe (B) or MV-infected Ifnar
ko
-SLAMGe mice (C). Cells were 
gated for CD11c
high
 (left panels), MHCII
low
 (center left panels), and Mac-1
low
 
(center right panels) and analyzed for infection (GFP) versus SLAM 
expression (right panels). Effect of MV infection on hSLAM expression in AM 
(D). X axis: FSC, forward scatter. Ifnar
ko
-CD46Ge mice were used as negative 
controls to set the quadrants. 
 
Importantly, about one in 11 SLAM-expressing AM were infected 
(Fig. 4C, compare numbers in top and bottom right panels), whereas one in 
28 SLAM-negative AM were infected (Fig. 4C, compare numbers in top and 
bottom left panels). Analysis of AM from additional four animals confirmed 
2-3 times preferential infection of SLAM-expressing cells (data not shown). 
These data confirm that infection of AMs in a SLAM-dependent manner is a 
crucial step in the early stages of MV infection. Enhanced hSLAM 
expression on infected and non-infected AM is short-lived: 3 days after 
infection, hSLAM expression returned to levels slightly above the values 
found on AM from mock infected mice (data not shown).  
 
Spread in the lymphatic organs. We further characterized MV 
spread by quantifying viral replication in different lymphatic organs of 
Ifnar
ko
-SLAMGe mice 3 days after IN inoculation. As shown in Figure 5A, the 
mediastinal LN was infected with high efficiency in two mice and at lower 
levels in other three animals, whereas the other lymphatic tissues 
(mandibular, mesenteric, and inguinal LN, and spleen) were infected at low 
or undetectable levels. Thus the mediastinal LN that drains the respiratory 
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tract appears to be a prominent site of MV replication after IN infection of 
Ifnar
ko
-SLAMGe mice, as well as knock-in hSLAM expressing mice (127). 
 
Figure 5. MV infection 
levels in lymphatic organs. 
Data were obtained three 
days after IN inoculation (A), 
three days after IP 
inoculation (B), or six days 
after IP inoculation (C). Each 
dot represents a single 
mouse. Group average is 
represented by a horizontal 
bar and detection limit by a 
dotted line. Man: 
mandibular LN; Med: 
mediastinal LN; Mes: 
mesenteric LN; Ing: inguinal 
LN; Spl: spleen. 
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We then asked whether this effect is due to the IN route of 
infection or to a stronger susceptibility of cells in the mediastinal LN to MV 
infection. We inoculated mice IP and compared replication levels in a LN 
located in the peritoneum (mesenteric), one in the thoracic cavity 
(mediastinal), and two control lymph nodes (mandibular and inguinal). 
Three days later lymphatic tissues were harvested and the viral load 
measured. Again, a high MV titer was documented in the mediastinal LN 
(Fig. 5B): in different mice 1-8% of the cells of this LN were infected 3 days 
p.i. The average levels of infected cells in the mandibular, mesenteric and 
inguinal LN, and the spleen, were 10-100 times lower, but the differences 
between different LN were not statistically significant. Six days p.i. (Fig. 5C) 
0.01-0.1% of the cells were infected in all lymph nodes and in the spleen.  
 Finally, we sought to identify which cells support MV replication in 
the mediastinal LN. A group of 6 Ifnar
ko
-SLAMGe mice was inoculated IP, 
mediastinal LN collected three days p.i., single cell suspensions obtained 
and GFP expression analyzed by flow cytometry. As shown in Table 3, 
lymphocytes were infected at the highest levels: 2 ± 0.7% of B cells (B220
+
), 
1.1 ± 0.3% of CD4
+
 T cells (CD3
+
CD4
+
), and 2 ± 0.4% of CD8
+ 
T cells 
(CD3
+
CD8
+
). DC (MHCII
high
CD11c
high
) were infected at similar levels (1.4 ± 
0.4% infection) but macrophages (CD11c
low
Mac-1
high
MHCII
high
) were 
infected at lower levels (0.6 ± 0.1%). We note that DC and macrophages 
account only for a small fraction of cells in the mediastinal LN, and thus 
that lymphocytes are by far the most abundant cell type infected.  
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TABLE 3. Percentile of infected cells in the mediastinal LN after IP 
inoculation
 a
 
             Cell type Day 3 Mock 
B cells (B220
+
) 2 ± 0.7 (362-851) <0.01 (0-1) 
CD4
+
 T cells (CD3
+
CD4
+
) 1.1 ± 0.3 (159-332) <0.01 (0-1) 
CD8
+
 T cells (CD3
+
CD8
+
) 2 ± 0.4 (188-313) 0.02 ± 0.01 (1-5) 
DC (MHCII
high
CD11c
high
Mac-1
low
) 1.4 ± 0.4 (18-54) 0.08 (0-2) 
Macrophages (CD11c
low
Mac-1
high
) 0.6 ± 0.1 (10-22) 0.01 (0-2) 
a
 average ± standard deviation (range of counts); group size was 6 animals 
(both groups) 
 
Discussion 
 A new small animal model of MV infection. Small animal models 
for measles do not exactly mimic the human disease but allow one to focus 
on particular aspects of infection. We focused our study on the question of 
which cells are infected immediately after respiratory inoculation, and 
documented that hSLAM-expressing AM, as well as DC, are the initial 
targets in the lungs. These cells may ferry the infection through the 
epithelial barrier. Similarly, recent work with wild type and selectively 
receptor-blind MVs (34, 99), and with a selectively receptor-blind canine 
distemper virus (196) brought evidence for a model of morbillivirus 
dissemination postulating that these viruses take advantage of SLAM-
expressing immune cells situated in the lumen of the respiratory tract of 
natural hosts to cross the epithelial barrier after contagion.  
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Our improved mouse model has an immune deficient background: 
we generated hSLAM transgenic mice whose innate immune system is 
compromised by the deletion of the interferon alpha receptor. As 
expected, the Ifnar
ko
 background allowed more extensive MV infections 
than the previously used STAT1-defective background (202). Minimal MV 
replication in hSLAM-expressing mice that are immune-competent did not 
allow a sensitive study of the cell type specificity of infection, and we do 
not know whether prevention of the interferon type I response induces a 
different cell type specificity of infection. However, we know this was not 
the case for other mouse strains expressing CD46 or hSLAM in an Ifnar
ko
 
background mice (127, 168), and we do not have indications of the 
contrary for our mouse strain.   
Most characteristics of the Ifnar
ko
 and the STAT1-defective strain 
were similar: for example, equivalent levels of SLAM expression were 
observed in different cell types. Moreover, in the STAT1-defective mice we 
reported enlarged lymph nodes and splenomegaly due to immune cell 
infiltration (202); similarly, six days post-inoculation we observed enlarged 
lymph nodes in the Ifnar
ko 
mice, and the weight of their spleens was on 
average double than normal (119.8 ± 23.4 mg versus 54.8 ± 6.2 mg in 
uninfected mice, average and standard deviation in groups of five mice).  
 The cell-type specificity of expression of hSLAM suggests that a wild 
type MV might infect certain target lymphocytes, 
monocytes/macrophages, and DC, in transgenic mice. Indeed we 
monitored and quantified MV entry in these cell types, and documented 
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predominant interactions with AM and DC one day after IN inoculation. To 
our knowledge, this report is the first direct analysis of the events that 
support primary MV replication and early viral spread in an animal model. 
Later, infection progresses to lymphatic tissues, with an early (2 days p.i.) 
involvement of the mediastinal LN. Lymphocytes sustain the bulk of MV 
infection not only in the mediastinal LN (Table 3) but also in other LN and 
lymphatic organs (data not shown). Thus, our model reproduces the 
lymphatic phases of the infections of MV and other morbilliviruses in their 
natural hosts (108, 194). 
 
Crossing the epithelial barrier: alternatives. One day after IN 
inoculation with 10
6
 TCID50, MV replication was documented in about 2.5% 
of AM and 0.5% of DC of hSLAM-expressing mice. MV replication was 
below detection levels in Ifnar
ko
 mice not expressing hSLAM, indicating that 
scavenging of infectious virus by Ifnar
ko
 AM rarely if at all results in 
productive infection. Since there are about 2 million AM in a mouse (191) 
about 5x10
4
 AM were productively infected and expressed GFP. Even if 
only 1 in 1000 infected AM crosses the lung epithelium, about 50 of these 
cells would have the opportunity to transmit infectivity to the lymphatic 
organs. AM are implicated in the translocation of particles from the lungs 
to the draining lymph nodes (66), a process that MV may exploit to cross 
the epithelial barrier: infected AM might migrate to the draining lymph 
nodes and spread infection to B and T lymphocytes. The fact that 
replication of a MV vaccine strain in CD46-expressing transgenic mice is 
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most prominent in macrophages after inoculation by three different routes 
(154) is consistent with these cells sustaining the immediate early phase of 
MV infection. Moreover, in Ifnar
ko
-CD46Ge mice in vivo depletion of AM 
resulted in strong local DC infiltration, virus infection of infiltrating DCs and 
macrophages, and ultimately higher virus titer in lymphatic tissues (154). 
Thus, while protecting other immune cells from infection, AM also support 
MV replication in the lungs, and are likely to be one of the pathways 
exploited by MV to cross the epithelial barrier.  
Another potential ferry for MV are DC present in the sub-epithelial 
tissues of the airways. We have observed that there are about 10 times 
less DC than AM in the lungs of mice, and estimate that about 0.5% of 
2x10
5 
DC, or about 1000 DC, are infected. It has been reported that DC 
infected with influenza virus rapidly migrate from the respiratory tract to 
the draining LN (56), beginning 2 hours after infection (98). Analogously, DC 
productively infected with MV might cross the epithelial barrier and rapidly 
disseminate virus in the lymphatic organs including the mediastinal LN. 
Alternatively, the virus would attach to DC through DC-SIGN but not 
replicate, and DC would trans-infect T lymphocytes (35). DC that carry low 
levels of MV may be detected inefficiently by flow cytometry, resulting in 
an under-estimation of the efficiency of infection. Finally, it is also possible 
that cell-free virus exploits breaks in the epithelial barrier to reach immune 
organs through the lymphatics, but the efficiency of AM and DC infection is 
consistent with either cell type being more important than epithelium 
leakage as primary mean for MV to cross the epithelial barrier. 
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SLAM expression and virus amplification. Ohno et al. (127) 
observed that the mediastinal LN is preferentially infected in mice 
expressing a human-mouse SLAM hybrid, and several lines of evidence in 
our study suggest that a similar phenomenon occurs in our mice expressing 
hSLAM. To assess whether this is simply explained by higher receptor 
expression, we measured hSLAM expression levels in this and the 
mesenteric, mandibular and inguinal LN of uninfected animals, but failed to 
document significant differences (data not shown). Thus the cause for 
preferential MV spread in the mediastinal LN remains to be determined. 
In transgenic mice (Fig. 4) as in human tonsillar tissue (30), MV 
infects predominantly, but not exclusively, immune cells expressing SLAM. 
We do not know if the apparently SLAM-independent entry really occurs: it 
is possible that hSLAM expression is undetectable with antibodies but still 
sufficient to facilitate viral entry. 
After IN inoculation with MV, hSLAM expression is enhanced in 
infected and non-infected AM. Similarly, induction of SLAM expression 
after MV infection was previously reported ex vivo in monocytes (11, 109). 
The mechanisms activating SLAM expression in both systems are unknown 
and could be indirect. Nevertheless, since SLAM is a low affinity self-ligand 
glycoprotein (107), increase of its expression in few target cells may cause 
a feed-back loop of cell activation. This feed-back loop may in turn sustain 
extremely rapid spread of Morbillivirus infections in natural hosts (194). 
The new mouse model developed in this study allowed 
characterization of the immediate early phases of wild type MV infection in 
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the respiratory airways of an interferon-defective host, and gave 
quantitative insights in the cell types supporting primary MV replication in 
the lungs of this host. Future studies will address the relative importance of 
AM and DC for supporting primary MV infection and ferrying virus through 
the epithelial barrier in mice, and the question of the levels of infection of 
these cells in interferon-competent hosts. 
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CHAPTER 4 
Pathways of lymphatic dissemination of measles virus 
attenuated and wild type strains in SLAM expressing mice 
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Abstract 
MV vaccine has outstanding safety and efficacy records but the 
mechanisms underlying its attenuation are poorly understood. We 
characterized the spread of a vaccine strain and compared with that of a 
wild type. We also characterized the host cells supporting early infection 
and dissemination in the lymphatics. We infected Ifnar
ko
-SLAMGe mice 
intraperitoneally with a MV vaccine strain (MVvac) or with a wild type 
strain (wtMV). To identify which cells sustained the wild type MV and the 
attenuated strain infection, several lymph nodes (LN) and spleen were 
collected one or three days after intraperitoneal (IP) inoculation and 
analyzed by confocal microscopy. One day after inoculation MV was 
detected in a macrophage population in the subcapsular sinus (SCS) of the 
mediastinal LN and marginal sinus (MS) of the spleen (here named SCS 
macrophages). Later, three days post infection, the wtMV efficiently spread 
to SLAM expressing leukocytes in the mediastinal LN and spleen whereas 
the vaccine strain was cleared. The spread of a wild type virus strain 
carrying a mutation in the H protein (N481Y) allowing CD46 binding in 
addition to SLAM did not alter viral tropism or replication efficiency. Thus, 
vaccine attenuation may be caused by suboptimal replication and early 
clearance by the host innate immune system. 
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Introduction 
Measles is preventable by a safe and effective vaccine. A 
vaccination program led to a significant reduction in the number of MV 
related deaths; since 2000 to 2008 the number of deaths related to MV 
decreased 78%, from 733.000 in 2000 to 164.000 in 2008 (1). However, in 
countries with poor health infrastructure measles remains a major cause of 
human mortality and morbidity.  
The current available measles vaccines are derived from the original 
Edmonston strain, isolated from a patient by Enders and Peebles in 1954 
(42). The live attenuated vaccines in use were obtained by passaging of the 
original strain in several cell lines, including human kidney and amnion cells 
and chicken embryo fibroblasts (59). The vaccine strain used here was 
obtained from an infectious cDNA derived from a vial of the Moraten strain 
(38). The Moraten is one of several attenuated strains derived from the 
original Edmonston clinical isolate and is identical to the Schwartz vaccine 
strain (137). 
We recently bred a mouse line expressing hSLAM in an interferon 
type I deficient background and documented that alveolar macrophages 
and dendritic cells support early MV replication in the respiratory tract. In 
addition, we observed early infection of all lymphatic organs, and in 
particular of the mediastinal LN, upon IP and intranasal (IN) inoculation. 
Based on this, we sought to compare the viral tropism and spread of a wild 
type strain with that of a vaccine strain in the lymphatic tissues. In 
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addition, we characterized the spread of a wild type strain carrying a single 
mutation in the H protein, an asparagine to tyrosine substitution at aa 481 
(N481Y), allowing CD46 binding in addition to SLAM. CD46 is the receptor 
used only by the attenuated MV strain (39, 119, 204).  
One day after IP inoculation we documented that MV colocalized 
with SCS and MS macrophages in the mediastinal LN and spleen, 
respectively. Later, wild type MV efficiently infected SLAM expressing 
leukocytes in the mediastinal LN. In contrast, the vaccine strain was cleared 
after an initial infection of SCS or MS macrophages. Thus, early clearance 
may account for the MV vaccine attenuation. 
 
Materials and Methods 
Cells. B95a (marmoset B-cell line kindly provided by Dr. Gerlier) and 
Vero cells were maintained in DMEM and 10% fetal bovine serum (FBS). 
Vero/hSLAM cells (Vero cells expressing human SLAM, kindly provided by 
Dr. Y. Yanagi) were maintained in DMEM supplemented with 10% FBS and 
0.5 mg of G418/ml. The rescue helper cell line 293-3-46 (147) was grown in 
DMEM with 10% FBS and 1.2 mg of G418/ml. 
 
Cell infections. B95a (5x10
5
 cells/well), Vero and Vero/hSLAM 
(2.5x10
5
 cells/well) were cultured on 12 well plate and infected with wtMV, 
MVvac, MVvacY481N, and wtMVN481Y at an M.O.I. of 0.1 in 0.5 ml of Opti-
MEM. Two hours later the opti-MEM was replaced by DMEM 
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supplemented with 10% FBS. Syncytia formation was photographed 24 to 
48 hours post infection (p.i.) under a phase-contrast microscopy. 
 
Mouse strains. Generation of Ifnar
ko
-SLAMGe mice was described in 
Chapter 3. To establish a transgenic mouse line expressing the hSLAM and 
hCD46 gene and deficient in the alpha/beta interferon response, Ifnar
ko
-
CD46Ge mice (113) were crossed with SLAMGe mice (202). To obtain 
Ifnar
ko
-CD46Ge-SLAMGe mice, the F2 and F3 progeny was screened for 
inactivation of both copies of the interferon alpha receptor gene as 
previously described (114) and for the availability of two copies of the 
hSLAM gene and hCD46 gene.  
 
Mouse infections. All animal experimental procedures were 
performed according to protocols previously approved by the Mayo Clinic 
Institutional Animal Care and Use Committee. Five to 8-week-old animals 
were infected IP with 1.5x10
6
 tissue culture infectious dose 50% (TCID50) 
MV to measure viral load in lymphatic tissues, or with 8x10
6
 TCID50 for 
detection of infected cells by flow cytometry or histology.  
 
Site-specific mutagenesis of measles virus H protein. The specific 
mutation (asparagine to tyrosine substitution at amino acid 481 (N481Y) or 
the reverse (Y481N) was introduced into the wild type measles and vaccine 
strain virus H genes with the Quickchange site-directed mutagenesis kit 
(Stratagene) on pCG-IC323-H or pCG-vac-H respectively. The mutated H, 
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HN481Y or HY481N, was cloned in the full length p(+)MV323 or 
pB(+)MVvac with PacI/SpeI. The full construct was named wtMVN481Y or 
MVvacY481N. 
 
Viruses and virus stock preparation. wtMV, wtMVCAT and MVvacCAT 
were previously described in Chapter 2 and wtMVgreen in Chapter 3. 
MVvac (38), MVvacY481N and wtMVN481Y were generated from full-
length cDNAs as descrived by Radecke et al. (147). Cells were scraped in 
Opti-MEM (Gibco/Invitrogen Corp.) and viral particles were released by 
two freeze-thaw cycles. Titers were determined by TCID50 titration on 
Vero/hSLAM cells according to the Spearman-Kärber method (86). 
 
Organ collection and preparation of single cell suspensions. Organ 
collection and preparation of single cell suspensions were as described in 
Chapter 3. 
 
Flow cytometry. As previously described in Chapter 3, SLAM 
expression was detected by incubating cells with PE anti-human CD150 
(A12, BD Pharmingen). Acquisition of samples was performed on a 
cytometer (FacsCanto) and analyzed using FlowJo software (Tree Star, Inc., 
Asland, OR). 
 
Immunofluorescence. Frozen sections, obtained as previously 
explained in Chapters 2 and 3, were incubated one hour at RT with 
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antibodies diluted according to manufacturer’s recommendations in 
blocking solution. MV N protein was detected with a rabbit polyclonal anti-
MV N antibody (described in Chapters 2 and 3) at a dilution of 1/100 
followed by incubation with Alexa Fluor 488-conjugated anti-rabbit IgG 
(Invitrogen, Molecular Probes, Eugene, OR). Subcapsular macrophages 
were identified with rat anti-mouse sialoadhesin (CD169) (clone 3D6.112; 
Abcam Inc., Cambridge, MA). Sections were mounted in Prolong Gold 
antifade reagent with DAPI (Invitrogen, Molecular Probes) and visualized 
with a Zeiss Axioplan confocal microscope (LSM 510; Carl Zeiss Inc., 
Germany). 
 
Quantification of virus load in lymphatic organs. Quantification of 
virus load in lymphatic organs was performed as described in Chapter 3.  
 
Results 
Low efficiency of replication of MV vaccine strain. As shown in 
Chapters 2 and 3, infection by the wild type MV upon IN or IP inoculation 
resulted in spread to several lymphatic organs, with preferential replication 
in the mediastinal LN. 
We then asked whether infection of an attenuated strain of MV, 
MVvac, reproduces the tropism and efficiency of infection as that of a wild 
type strain. To quantify and characterize the spread of an attenuated strain 
of MV, Ifnar
ko
-SLAMGe mice were inoculated IP with MVvac; three days 
later the lymph nodes and spleen were harvested and the viral load 
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measured. As shown in Figure 1, panel A, MVvac infected the mediastinal 
and mesenteric LNs and spleen about 100 times less efficiently as 
compared to wtMV (panel B). The infection levels of mandibular and 
inguinal LN by the attenuated strain were undetectable (panel A). Although 
infection of the lymphoid tissues was generally low, the mediastinal LN 
supported the highest level of infection. Thus, in this animal model, the 
vaccine strain replication is very inefficient compared to wild type.  
 
                                                         
 
Figure 1. MVvac (A) and wtMV (B) infection levels in lymphatic organs 
three days after IP inoculation. Each dot represents a single mouse. Group 
average is represented by a horizontal bar and detection limit by a dotted 
line. Man: mandibular LN; Med: mediastinal LN; Mes: mesenteric LN; Ing: 
inguinal LN; Spl: spleen. (Panel B is from Chapter 3, Fig. 5B).  
 
 
Early capture of wild type and vaccine strains of MV by 
subcapsular macrophages. We next sought to identify which cells support 
early infection by the wtMV and MVvac strains in the lymphatic tissues and 
A
                 
B 
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whether the tropism of these two strains differs. To characterize the initial 
targets of MV infection in the lymphoid tissues, Ifnar
ko
-SLAMGe mice were 
inoculated IP with wtMVgreen or MVvac and were sacrificed one or three 
days after infection. The mediastinal LN and spleen were collected and 
frozen sections were obtained and stained with anti-N antibody to 
detected viral protein. As shown in Figures 2 and 3, panels A and C, one day 
p.i. wtMV and MVvac viruses were localized mainly in the SCS of the 
mediastinal LN and to a lesser extent in the MS of the spleen (green 
colour).  
The subcapsular sinus of LN is an area rich in macrophages (28, 48) 
and, recently, VSV was shown to colocalize with a macrophage marker, 
CD169 in the subcapsular sinus of LN early after injection into the footpad 
(84). This macrophage population, SCS macrophages, is characterized as 
CD169
+
 Mac-1
+
 MHCII
+
 and CD11c
low
 (84). To assess whether MV replicates 
in SCS macrophages, Ifnar
ko
-SLAMGe mice were infected IP with wtMV or 
MVvac. Frozen sections of LN and MS of spleen were double stained with 
anti-CD169 (red) and anti-MVN (green) antibodies. Figures 2 and 3 (A and 
C) shows that one day p.i. MV wild type and vaccine strains colocalized 
mainly with SCS macrophages in the mediastinal LN and spleen.  
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Only wild type MV infection progresses to B and T cell areas. We 
next infected Ifnar
ko
-SLAMGe mice IP with wtMV or MVvac, and assessed 
progression of infection in the mediastinal LN and spleen. Three days p.i. 
these organs were harvested, frozen sections obtained and stained with 
anti-MV N and anti-CD169 antibodies. Three days after inoculation the 
colocalization of wild type or vaccine strains with the SCS macrophages was 
strongly reduced (Figs. 2 and 3, B and D). However, MV wild type replicated 
extensively and spread to the B and T cell areas of the LN (below the SCS) 
and spleen (white pulp area represented by a white dotted circle) (Figure. 
2, panels B and D), whereas the vaccine strain did not (Figure 3, panels B 
and D). This suggests that only wild type can escape capture by SCS and MS 
macrophages in the LN and spleen and continue replicating; replication of 
the vaccine strain is impaired after capture by SCS macrophages. 
Results  Chapter 4 
 
111 
 
 
Figure 2. Characterization of wtMV-infected cells in the lymphatic organs 
one and three days after IP inoculation of Ifnar
ko
-SLAMGe mice. 
Identification of the cell types accumulating MV N, by confocal micrographs 
analysis. Frozen sections of mouse mediastinal LN (A and B) or spleen (C 
and D) stained with an anti-N and anti-CD169 antibodies. N protein was 
visualized with Alexa Fluor 488 (green). The macrophage marker, CD169, 
was visualized with Alexa Fluor 594 (red). Nuclei were counterstained in 
blue with DAPI. Scale bars represent 200 µm. Scale bar for insert in panel A 
represent 10 µm. 
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Figure 3. Characterization of MVvac-infected cells in the lymphatic organs 
one and three days after IP inoculation of Ifnar
ko
-SLAMGe mice. 
Identification of the cell types accumulating MV N, by confocal micrographs 
analysis. Frozen sections of mouse mediastinal LN (A and B) or spleen (C 
and D) stained with an anti-N antibody. N protein was visualized with Alexa 
Fluor 488 (green). The macrophage marker, CD169, was visualized with 
Alexa Fluor 594 (red). Nuclei were counterstained in blue with DAPI. Scale 
bars represent 200 µm (A to C) and 50 µm (D). 
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Next we sought to assess whether infection in the mediastinal LN 
correlates with SLAM expression. A group of 6 Ifnar
ko
-SLAMGe mice were 
infected IP with wtMVgreen, three days later the mediastinal LN was 
collected and leukocytes were analyzed for GFP versus SLAM expression by 
flow cytometry. Leukocytes from mock-infected Ifnar
ko
-SLAMGe mice and 
from non infected Ifnar
ko
-CD46Ge mice served as controls. Figure 4A (right 
quadrants) shows that background (0.81%; 0.75% plus 0.06%) hSLAM 
expression was detected in leukocytes from control Ifnar
ko
-CD46Ge mice 
whereas 11.61% (11.57% plus 0.04%) and 13.25% (11.54% plus 1.71%) of 
leucocytes from mock-infected Ifnar
ko
-SLAMGe mice and infected Ifnar
ko
-
SLAMGe mice respectively expressed hSLAM (Figs. 4B and C, right 
quadrants). Importantly, about one in 8 SLAM-expressing leukocytes were 
infected (8.3 ± 2.7; average ± standard deviation) (Fig. 4C, compare 
numbers in top and bottom right panels), whereas one in 96 SLAM-
negative leucocytes were infected (94.5 ± 32.65, average ± standard 
deviation) (Fig. 4C, compare numbers in top and bottom left panels). Thus, 
these results confirm the relevance of infection of SLAM expressing 
leukocytes in MV propagation.  
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Figure 4. Analysis of hSLAM expression in immune cells from the 
mediastinal LN before and after MV infection. Leukocytes from non-
infected Ifnar
ko
-CD46Ge mice (A), mock-infected Ifnar
ko
-SLAMGe (B) or MV-
infected Ifnar
ko
-SLAMGe mice (C). Cells were gated for live cells and 
analyzed for infection (GFP expression) (top quadrants) versus SLAM 
expression (right quadrants).  
 
Replication of a recombinant wild type MV with a single mutation 
allowing different receptor usage. Because the vaccine strain can enter 
cells through CD46 in addition to SLAM whereas the wild type only uses 
SLAM, we asked whether low efficiency of infection of this virus was 
dependent on cellular receptor usage. In a pilot study, one group of 3 mice 
expressing hCD46 in addition to hSLAM, here named Ifnar
ko
-CD46Ge-
SLAMGe, and one group of mice expressing hSLAM, Ifnar
ko
-SLAMGe, were 
infected intranasally with MVvac expressing the reporter gene CAT. 
Another group of 3 Ifnar
ko
-SLAMGe mice was infected with wtMVCAT. The 
lungs, spleen and thymus were collected and analysed for CAT activity 
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three days after inoculation. Upon IN infection, the vaccine strain was 
detected at low levels only in the thymus of one Ifnar
ko
-CD46Ge-SLAMGe 
animal and in the lungs of one Ifnar
ko
-SLAMGe animal; in contrast, the wild 
type virus was detected in the lungs of all Ifnar
ko
-SLAMGe mice, in the 
spleen of two out of three Ifnar
ko
-SLAMGe animals and in the thymus of 
one Ifnar
ko
-SLAMGe animal (data not shown). Thus, vaccine strain infection 
is very inefficient and this inefficiency seems to be independent of receptor 
usage. 
Adaptation to growth in certain cell lines results in the selection of 
certain mutations in MV genomes (136, 137). One frequent mutation is the 
substitution of an asparagine to tyrosine at amino acid 481 (N481Y) in the 
H protein. This mutation is absent in the wild type strains but common to 
all vaccine strains and is linked to the ability of the virus to use an 
alternative receptor for entry into cells, CD46 (76, 97). CD46, a 
complement regulatory protein, is expressed in all nucleated cells and the 
usage of this receptor in addition to SLAM may play a role in vaccine 
attenuation. To confirm or deny whether this mutation and adaptation in 
receptor specificity alters replication efficiency of MV, we characterized the 
replication of a wild type MV with an asparagine to tyrosine substitution in 
the hemagglutinin protein allowing binding to CD46. 
We generated a wild type virus with an asparagine to tyrosine 
substitution and a vaccine virus with a tyrosine to asparagine substitution 
in the hemagglutinin protein, wtMVN481Y and MVvacY481N, respectively. 
We first documented receptor usage by wtMV, wtMVN481Y, MVvac and 
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MVvacY481N, using several cell lines expressing CD46 and/or SLAM. Figure 
5A (top row) shows that all viruses (wtMV, wtMVN481Y, MVvac and 
MVvacY481N) induce syncytia on B95a cells, expressing SLAM but not 
CD46, whereas only wtMVN481Y and MVvac can fuse Vero cells, expressing 
only CD46 (second row). However, MVvac induced syncytia in Vero cells 
more efficiently than wtMVN481Y virus. Substitution of a tyrosine to 
asparagine in MVvac abolishes CD46 usage and this virus no longer fuses 
Vero cells (second row). All viruses can infect Vero cells expressing SLAM 
(third row). Thus, the N481Y mutation allows the wild type MV to infect 
cells expressing CD46 without compromising its ability to use SLAM 
receptor. 
 wtMV and wtMVN481Y grew to similarly high titers in vitro in 
Vero/hSLAM cells (not shown). To analyse whether wtMVN481Y replicates 
as efficiently as the wtMV in vivo, we infected Ifnar
ko
-SLAMGe mice IP with 
wtMVN481Y or wtMV; three days after inoculation the viral replication was 
measured in several lymph nodes (mandibular, mediastinal, mesenteric, 
and inguinal LN) and spleen. Fig. 5 B and C graphs, shows that wtMV and 
wtMVN481Y moderately infected the mandibular, mesenteric and inguinal 
LNs whereas the mediastinal LN and the spleen were infected with higher 
efficiency. The wtMV replicated slightly more efficiently in the mediastinal 
LN than the wtMVN481Y whereas the wtMVN481Y infected in average 10 
times more the spleen compared to wtMV. But overall, both viruses 
replicated efficiently in Ifnar
ko
-SLAMGe mice. 
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 Next, we sought to analyse whether the ability to infect cells 
through CD46 in addition to SLAM would affect viral replication. Towards 
this, we inoculated a mouse strain expressing hCD46 in addition to hSLAM, 
and bred in an interferon type I deficient background, named Ifnar
ko
-
CD46Ge-SLAMGe mice. Infection of Ifnar
ko
-SLAMGe mice served as a 
control. A group of 6 Ifnar
ko
-CD46Ge-SLAMGe mice and a group of 6 Ifnar
ko
-
SLAMGe mice were infected with wtMVN481Y and several lymphatic 
organs (lymph nodes and spleen) were collected and the viral load was 
assessed 3 days after infection. As shown in Figs. 6A and B, wtMVN481Y 
replicated equally well in Ifnar
ko
-SLAMGe mice and in Ifnar
ko
-CD46Ge-
SLAMGe mice. Thus, N481Y mutation and CD46 usage does not seem to 
affect replication of the wild type strain of MV, at least in this animal 
model. 
 
   A 
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     B                                          C 
 
                                            Ifnarko-SLAMGe mice 
 
 
Figure 5. Characterization of a recombinant MV containing an H protein 
with an asparagine to tyrosine substitution at position 481 (N481Y 
mutation), wtMVN481Y. (A) Differential receptor usage by MV carrying a 
mutation in the hemagglutinin protein. Different cell types expressing 
different receptors (indicated at the left of each row) were infected by 
several viruses (indicated at the top of each column) at an MOI of 0.1. 
Syncytia formation was photographed 24 to 48 hours later under phase-
contrast microscopy. 
(B) Replication of wtMV and (C) wtMVN481Y in several lymphatic organs of 
Ifnar
ko
-SLAMGe mice. Titers were measured 3 days after IP inoculation. 
Each dot represents a single mouse. Group average is represented by a 
horizontal bar and detection limit by a dotted line. Man: mandibular LN; 
Med: mediastinal LN; Mes: mesenteric LN; Ing: inguinal LN; Spl: spleen. 
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A                                               B 
 
Figure 6. wtMVN481Y infection levels in lymphatic organs of 
Ifnar
ko
SLAMGe (A) or Ifnar
ko
CD46Ge-SLAMGe mice (B) three days after IP 
inoculation. Each dot represents a single mouse. Group average is 
represented by a horizontal bar and detection limit by a dotted line. Man: 
mandibular LN; Med: mediastinal LN; Mes: mesenteric LN; Ing: inguinal LN; 
Spl: spleen.  
 
Discussion 
We previously showed that wild type MV after initial replication in 
the lungs spreads to several lymphatic organs; the mediastinal LN 
supported higher levels of infection. We report here that the efficiency of 
infection of the mediastinal LN and other lymphatic tissues by the vaccine 
strain is significantly lower than that of the wild type. As observed in 
studies in human tonsillar tissue, with the exception of naïve T 
lymphocytes, the efficiency of infection of different cell populations by the 
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vaccine strain was significantly lower than that of the wild type (30). We 
also show that wild type infection of SCS macrophages is followed by 
extensive replication in SLAM expressing leukocytes. In contrast, after an 
initial interaction with SCS macrophages the vaccine strain of MV does not 
propagates as efficiently as the wild type. Thus, initial encounter with 
macrophages in the secondary lymphatic organs might be fatal for the 
vaccine strain; whereas the wild type overcomes this barrier and 
disseminates to lymphocytes. 
Subcapsular sinus macrophages are resident macrophages lining 
the sinuses of the secondary lymphoid organs involved in filtering 
pathogens out of the lymph or blood. These macrophages are poorly 
endocytic and have low degradative capacity which enables them to 
present intact antigen on their cell surface (84). In fact, electron 
microscopy studies of captured VSV reported virions on the cell surface and 
also in vacuoles of SCS macrophages (84, 141). It has been reported that B 
cells, located immediately beneath the subcapsular sinus in the secondary 
lymphoid organs, are able to capture antigens from SCS macrophages (21, 
84, 141). Analogously, SCS macrophages infected with MV might present 
infectious viral particles to B lymphocytes; a process that MV may exploit 
to secure efficient infection and spread. Moreover, following capture of 
MV SCS macrophages themselves might become infected and therefore 
constitute an early viral reservoir. This associated to the low degradative 
capacity of these cells may make them a safe sanctuary for the wild type 
MV.  
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We next asked whether the N481Y mutation selected during 
adaptation to certain cultivated cells, would affect the tropism or 
replication efficiency of MV. We showed that the mutated strain as well as 
the parental strain replicated efficiently in the lymphatic organs of Ifnar
ko
-
SLAMGe mice, suggesting that the mutation did not affect replication 
ability. We further showed that wtMVN481Y replicated as efficiently as 
wtMV in Ifnar
ko
-SLAMGe and Ifnar
ko
-CD46Ge-SLAMGe mice. Thus, 
adaptation to entry through CD46 does not strongly alter the tropism of 
the virus in vivo. Additional mutations acquired by attenuated strains such 
as S546G, N390I, N416D, T446S, T484N and E492G seem to increase the 
viral binding affinity for CD46 (155, 162, 167, 176). Thus, it is conceivable 
that a wild type virus with all these mutations may enter cells preferably 
through CD46 instead of SLAM with a possible implication in viral tropism 
and attenuation.  
On the other hand, besides mutations in the H protein, cell culture 
adaptation of MV has generated several amino acid substitutions in P, C, V 
and M proteins of the virus (8, 180, 181, 184). These genetic changes might 
affect viral replication, maturation or interaction with host proteins and 
may have a cumulative effect on attenuation. Whatever the mechanism or 
mechanisms underlying MV vaccine attenuation are, escape from 
macrophage infection appears to be a key aspect of attenuation.  
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CHAPTER 5 
Main conclusions and future perspectives 
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 This thesis aimed at a better understanding of the interaction 
between MV and the cellular receptor SLAM and the consequences for MV 
spread and pathogenesis. Towards this we characterized the spread of MV 
in a transgenic mouse expressing human SLAM, the cellular receptor for 
wild type and attenuated strains of MV. 
 These studies provided valuable insights about MV initial target 
cells upon respiratory infection as well as the development of infection in 
the lymphatic system. Moreover we bred a transgenic mice expressing 
hSLAM into an IFNAR deficient background and we used these mice to 
show that alveolar macrophages and dendritic cells are the major target 
cells immediately after intranasal infection. Infection in the airways was 
short lived and early the virus spread to the lymphatic tissues. The 
mediastinal LN was the LN where the virus reached the highest titre. In the 
lymphatic tissues we documented an early involvement of MV with a 
specific population of macrophages, SCS macrophages, localized in the 
subcapsular sinus of the mediastinal LN and marginal sinus of spleen. Later 
the virus spread to the follicular areas and extensively replicated in SLAM 
expressing immune cells. In contrast, MV vaccine strain seems to be 
impaired by this population of macrophages; after initial infection of SCS 
macrophages the vaccine strain showed low levels of replication. Thus, 
macrophages seem to play a dual role: they might serve as an early 
reservoir of MV and seed infection to other lymphatic cells but they also 
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protect the host from uncontrolled viral dissemination as documented in 
the case of the attenuated strains of MV. 
  
 Briefly the main conclusions are presented here as follows: 
 
 In Chapter 2 
• We showed that SLAM transgenic mice expressed hSLAM 
with human like tissue specificity; hSLAM expression in B 
and T lymphocytes and in macrophages is dependent on the 
activation status of the cells. Resting B and CD4 and CD8 T 
and macrophages expressed hSLAM at low levels whereas 
activation increased hSLAM expression; 
 
• We documented that macrophages from Ifnar
ko
-SLAMGe 
mice support MV infection ex vivo in a receptor-dependent 
manner;  
 
• We showed that Ifnar
ko
-SLAMGe mice are susceptible to MV 
infection after IP or IN inoculation; several lymphatic tissues 
and non lymphatic tissues supported replication of MV. 
 
Thus, these mice are suitable to assess the relevance of receptor 
usage for MV infection and should give insights into the early steps of MV 
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infection and into the mechanism of MV pathogenesis including 
immunosuppression.  
 
 In Chapter 3 
 We took advantage of mice expressing SLAM with human like tissue 
specificity, Ifnar
ko
-SLAMGe mice, to characterize the early steps of MV 
infection. Moreover, we identified the initial target cells after respiratory 
infection. 
 
•  We identified alveolar macrophages and dendritic cells as 
the cells that sustain MV replication immediately after 
respiratory infection; these cells expressed hSLAM; 
 
•  We documented that MV infection of alveolar macrophages 
temporarily enhanced SLAM expression in these cells. Thus, 
MV infects cells that easily up-regulate its receptor, 
improving spread and infection efficacy; 
 
• We showed that one day after initial replication in the 
alveolar macrophages the virus disseminated to the 
lymphatic system with early involvement of the mediastinal 
LN. Furthermore, the mediastinal LN supported the highest 
titre after IN or IP inoculation. In the mediastinal LN MV 
infected immune cells such as B and T lymphocytes. 
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 In Chapter 4 
 The mechanisms underlying MV vaccine attenuation are not well 
understood. We compared the spread of an attenuated strain of MV with 
that of a wild type in an animal model expressing hSLAM.  
 
•  We showed that MVvac replication was very inefficient in 
the lymphatic tissues of Ifnar
ko
-SLAMGe mice. Infection of 
mediastinal LN and spleen by the vaccine strain was 100 
times less efficient as that of a wild type strain. Infection of 
other lymph nodes was under detectable levels;  
 
• We documented by confocal microscopy that at one day p.i. 
both, the vaccine and the wild type viruses were retained in 
the subcapsular sinus of mediastinal LN and in the marginal 
sinus of the spleen; the virus colocalized with a specific 
population of macrophages, the subcapsular sinus 
macrophages. Subcapsular macrophages are typically 
present in the SCS and MS of lymph nodes and spleen 
respectively and play an important protective role by 
sampling pathogens in the lymphatic organs; 
 
• We showed that infection of SCS macrophages by the wild 
type is preceded by massive infection of SLAM expressing 
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lymphoid cells in the lymphoid tissues whereas the 
replication of the vaccine strain is disallowed after 
interaction with the macrophages; 3 days after IP infection 
the vaccine strain was almost cleared from the mediastinal 
LN and spleen;  
 
• We showed that adaptation to CD46 usage by the wild type 
MV, in addition to SLAM, has little influence on MV virulence 
and does not alter viral tropism. 
 
 
 Three characteristics of the mouse model used in these studies, 
Ifnar
ko
-SLAMGe mouse, allowed the study of the early phases of MV 
infection. First, infection of these animals resulted in extensive viral 
replication due to an interferon defective response without affecting the 
specificity of MV replication (127, 154). Second, the expression of the 
lymphatic MV receptor, SLAM, in these animals allowed the 
characterization of the early stages of MV infection and lymphatic 
dissemination. And third, this mouse does not express the basolateral 
epithelial cell receptor necessary for MV to leave the host (99) but allowed 
characterization of the early stages of infection and spread of the virus in 
the lymphatic tissues. This animal model gave insights in the cellular 
targets supporting primary MV replication. Future studies are necessary to 
understand whether the conclusion that the AM and DC are the early and 
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primary target cells can be extended to infection of the natural hosts. 
Further studies into the mechanism(s) of how the virus crosses the 
epithelial barrier and achieves dissemination throughout the body are 
necessary.  
 It is interesting that replication of MV is detected in the 
macrophages by two different routes of infection. AMs have been 
implicated in the transport of particles and pathogens from the lungs to the 
draining LN (66, 89), whereas SCS macrophages were shown to guide 
captured virions across the SCS of the lymph nodes for efficient 
presentation and activation of B cells (84, 85). MV may exploit these 
characteristics to achieve dissemination throughout the host permissive 
cells. Further research will be required to determine how the virus infected 
macrophages achieves dissemination to other immune cells. The fact that 
after interaction with the macrophages the wild type MV propagates 
efficiently whereas the vaccine does not is puzzling. The low efficiency of 
replication may disable the vaccine strain to counteract the innate immune 
response and thus plays a role in viral attenuation.  
 Understanding the interactions of MV with macrophages and 
dendritic cells may open new avenues for the development of more 
efficient vaccines and novel therapeutic approaches. 
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